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CHAPTER 1- INTRODUCTION:
1.1 ATR and the DNA Damage Response
The DNA damage response (DDR) works together with DNA repair proteins in order to
protect the cell from endogenous or environmental DNA-damaging agents or replication stress
(1). Replication stress can come in the form of chemical modifications to nucleosides or DNA
bases, aberrant DNA secondary structures, aberrant DNA binding proteins along the path of
replication, low dexoynucleoside triphosphate (dNTP) pools, or collisions between the
transcription and replication machineries (2,3). The main functions of the DDR are to arrest the
cell cycle, recruit DNA repair proteins, and to initiate apoptosis if the damage is severe (4).
Genes involved in the DDR are typically tumor suppressors because they prevent mutations in
critical proto-oncogenes or tumor suppressors that could lead to cellular transformation (5).
However, transformed cells can become reliant on DDR pathways in order to avoid apoptosis, so
DDR genes can also be thought of as oncogenes and therefore potential targets for cancer
therapy (6). Depending on the stage of the cell cycle and what type of damage is involved,
different DDR pathways can be activated.
The main pathway that deals with DNA damage detected specifically in the S or G2
phases of the cell cycle involves the ataxia telangiectasia mutated and Rad3-related (ATR)
protein kinase (7,8). ATR is in the phosphatidylinositol 3-kinase-related kinase (PIKK) family
and works to stabilize replication forks in response to DNA damage or replication stress (9,10).
In response to replication stress or nucleotide excision repair intermediates, single-strand DNA
(ssDNA) is formed. In addition to these scenarios, DNA double strand breaks (DSBs) can be
resected to form ssDNA tails with 3’ ends, or depletion of dNTPs can result in ssDNA around
replication forks (11). Next, ssDNA is coated with replication protein A (RPA), which interacts
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with ATR-interacting protein (ATRIP) and activates ATR (12). ATR activation also requires
localization of the heterotrimeric ring shaped 9-1-1 complex (made up of RAD9, RAD1, and
HUS1) to the damaged site. This localization is accomplished through the interaction of RPA
with RAD17. The 9-1-1 complex then recruits topoisomerase binding protein-1 (TOPBP1),
which is crucial for ATR activation (13,14). Claspin brings ATR and checkpoint kinase 1
(CHK1) into close proximity, and ATR then catalyzes phosphorylation of CHK1 (15). CHK1
catalyzes phosphorylation of a host of proteins, including WEE1, CDC25A, and CDC25C to
arrest the cell cycle. These phosphorylation events serve to inhibit cyclin-dependent kinase
(CDK) activity. Inhibition of CDK1 results in G2/M arrest and inhibition of CDK2 results in S
phase arrest (11). The ATR pathway also regulates activity and recruitment of DNA repair
proteins. An early target of ATR signaling is histone H2AX; ATR catalyzes its phosphorylation
to form γ-H2AX (16,17). γ-H2AX can then recruit DNA repair proteins and potentiates the DDR
signal (18,19). ATR catalyzes phosphorylation of Fanconi-anemia proteins to promote
localization to sites of cross-linked DNA damage (20). ATR can also recruit nucleotide excision
repair proteins to DNA lesions by phosphorylating XPA (21). ATR activates BRCA1 through
phosphorylation, thereby activating homologous recombination repair (HRR), which is a key
DNA DSB repair mechanism. CHK1 phosphorylates and recruits RAD51 and BRCA2, which
are also involved in HRR (11) (see Figure 1.1).
ATR is an essential gene in mice, displayed by the fact that an ATR null environment
causes early embryonic lethality. These cells endure massive spontaneous chromosomal
fragmentation, leading to cell death (22). Mouse cells with hypomorphic ATR accumulate DNA
damage during S phase, and these mice experience an increased tumor incidence and early aging
(22,23). Mutations causing hypomorphic ATR in humans are associated with Seckel syndrome,
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Figure 1.1 Visual representation of the canonical ATR/Mec1 signaling pathway. See text for
details. This figure was adapted from (24).
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exemplified by severe developmental defects including microcephaly, severe growth retardation,
and intellectual disability (25,26). This indicates the essential role of ATR in early development.
Partial loss of ATR function also makes cells more susceptible to DNA-damaging agents.
Overexpression of a catalytically inactive ATR mutant causes hypersensitivity to DNAdamaging agents (7). ATR inhibition by caffeine causes radiosensitivity (27). ATR is also
involved in recruitment of proteins associated with the replication fork after replication stress is
induced (28). ATR inhibits transcription around stalled replication forks after treatment with
doxorubicin (29). This illustrates the diverse functions of ATR in protecting genomic integrity in
response to different types of stressors.
Although ATR is typically thought of as a tumor suppressor since it maintains genomic
integrity (5,30), it can also facilitate carcinogenesis by preventing apoptosis in transformed cells.
Cancer cells typically show elevated rates of replication stress, and the ATR pathway is critical
in preventing excess DNA damage resulting from replication stress, which could lead to
apoptosis or inviability (31,32). In a similar fashion, ATR is involved in the response to DNAdamaging chemotherapy agents in cancer cells and could function as a method of resistance to
cancer chemotherapy drugs (33-35). Other DDR pathways, which include the p53 and ATM
tumor suppressors, are often mutated and/or inactivated in cancer cells (31,36). This creates a
situation where cancer cells are dependent on the DDR pathway involving ATR in order to
handle replication stress and DNA damage and thereby avoid apoptosis (37). These findings
have led to the development of ATR inhibitors as a targeted therapy for cancer treatment. Several
ATR inhibitors are currently being tested in clinical trials as a monotherapy or in combination
with radiotherapy or DNA-damaging chemotherapy drugs such as carboplatin (37,38). The
combination approach is related to synthetic lethality. If the DDR is inhibited while DNA
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damage is being induced, then cancer cells should have no method of repairing DNA and will
succumb to cell death.
1.2 MEC1: The Yeast Ortholog of ATR
S. cerevisiae Mitosis Entry Checkpoint 1 (Mec1) is structurally similar to human ATR
and serves the same functional role (12,39). MEC1 is an essential gene (40); however, deletion of
Suppressor of MEC1 Lethality 1 (SML1) can circumvent the lethality induced by deletion of
MEC1. This occurs because during an unperturbed cell cycle the essential role of MEC1 is to
regulate dNTP levels, and SML1 is a negative regulator of dNTP levels (41). Deletion of MEC1
causes ssDNA bound by RPA to build up at replication forks and ultimately leads to DSB
formation (42). In response to DNA damage or replication stress, Mec1 activates the Dun1
kinase, which inhibits Sml1 activity and thereby increases dNTP pools (43). Mutations in MEC1
cause cells to be hypersensitive to DNA-damaging agents (44-46). In response to replication
stress, mec1 mutants lose control over replication initiation, which leads to an inability to restart
replication fork progression. The cells then prematurely enter mitosis, which ultimately causes
loss of viability (47). This indicates the differential functions of MEC1 in response to stress
versus during normal cell cycle progression.
Rad53 is a major target of Mec1 signaling in yeast and plays a similar functional role as
human CHK1; (48) however, the human structural ortholog of Rad53 is CHK2 (49). Mec1
catalyzes phosphorylation of Rad53, which is dependent on the Rad9 mediator protein (50).
Rad53 then autophosphorylates, which increases kinase activity by 9-fold (51). Like CHK1,
Rad53 then goes on to catalyze phosphorylation of a number of substrates to induce cell cycle
arrest, upregulate DNA repair proteins expression, and stabilize replication forks (52-55).
Another key target of Mec1 is H2A. Analogous to human ATR catalyzing phosphorylation of γ-
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H2AX, Mec1 catalyzes phosphorylation of H2A to generate γ-H2A, which promotes DSB repair
(56,57) (see Figure 1.1).
The Mec1 pathway is also intimately involved in regulation of transcription. Chromatin
restructuring from the generation of γ-H2A could be a mechanism that inhibits transcription in
response to stressors in yeast. In response to replication stress, proteins involved in regulating
transcription were found to be phosphorylation substrates of Mec1 and a related PIKK, Tel1, the
ortholog of human ATM (58). Mec1 senses nutrient deprivation and can downregulate Snf1 in
order to lead the cell away from respiration toward fermentation, analogous to the Warburg
effect in cancer cells (59). Mec1 also functions in preventing conflicts between the replication
and transcription machineries, which can be caused by stalled replication forks (60).
Hydroxyurea (HU) treatment causes replication fork stalling by depleting nucleotide pools and
also induces gene transcription, which causes conflicts between the two machineries and
eventually chromosome breakage (61). Mec1 functions in resolving stalled replication forks, as
stated earlier, and Mec1 also evicts transcription machineries. When replication and transcription
are conflicting, Mec1 plays a role in removing RNA Polymerase II from DNA to preserve
replication fork integrity (62). Mec1 also functions in detaching transcribed genes from the
nuclear pore complex to protect replication forks in replication-transcription conflicts (63).
1.3 DBF4 in the DDR and DNA Replication
A key downstream target of the DDR is the replication machinery, which is inhibited in
order to prevent replication fork stalling upon collision with DNA damage. ATR catalyzes
phosphorylation of MCM2, a component of the MCM2-7 helicase complex that initiates DNA
replication (64,65). Two other key downstream components of the Mec1 pathway that regulate
origin firing are Sld3 (66) and Dbf4 (67-69). Sld3 is an essential protein that associates with
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Cdc45 and functions in unwinding origins and initiation of DNA replication (70). Dbf4 is the
regulatory subunit of the Cdc7 kinase that catalyzes phosphorylation of the MCM2-7 helicase
complex to assist in initiation of DNA replication (71-73). Together, Dbf4 and Cdc7 make up
Dbf4-dependent kinase (DDK). Sld3 and Dbf4 phosphorylation is important for preventing late
origin firing in response to replication stress or DNA damage (66,68). Dbf4 physically interacts
with Rad53 (74-77) and is required to sustain the hyperphosphorylated state of Rad53 (78).
Dbf4 function has been studied extensively in S. cerevisiae. DDK is involved in meiotic
progression (79), replication checkpoint activation (78), translesion synthesis (80), histone
regulation (81), and exit from mitosis (82). Cdc7 levels stay constant throughout the cell cycle,
but Cdc7 is catalytically inactive until bound to Dbf4 (83,84). In contrast, Dbf4 expression is
highest in late G1 and S phases of the cell cycle, and Dbf4 is degraded after mitosis is complete
(83,85-88). Since Dbf4 is required to be in complex with Cdc7 in order for it to be catalytically
active, Dbf4 expression regulates Cdc7 activity throughout the cell cycle. Phosphorylation of
Dbf4 inhibits its activity, thereby inhibiting MCM phosphorylation and origin firing. In this way,
Dbf4 is a key downstream target of the DDR to inhibit DNA replication when the cell cycle has
been arrested (89).
Proteins involved in the DBF4 and ATR pathways directly and indirectly interact in
several ways. In response to replication fork stalling, Rad53 catalyzes phosphorylation of Dbf4,
which prevents late origin firing (66,68,88,90). In human cells, the mediator of ATR
phosphorylation of CHK1, Claspin, interacts directly with Cdc7. Claspin can recruit Cdc7 to
DNA for efficient phosphorylation of the MCM complex (91). CDC7 also catalyzes
phosphorylation of Claspin in the replication checkpoint (92,93). ATR has been shown to
directly catalyze phosphorylation of DBF4 and inhibit DNA replication. However, CDC7
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catalytic function was not compromised by phosphorylation of DBF4 by ATR. This
phosphorylation was also shown to be important for preventing DNA rereplication (94).
The overarching theme for these studies is to examine the functional roles of ATR/MEC1
in response to different stressors such as gene deletion or DNA rereplication. One aim of these
studies is described in Chapter 2, which demonstrates the functions of MEC1 and DBF4 in
preventing DNA rereplication during meiosis. ATR is important during meiotic checkpoints, so
these studies could provide a greater understanding of how meiotic mechanisms can become
defective and possible causes of infertility or genetic disorders. The other aim is described in
Chapter 3, which investigates how ATR/MEC1 and DBF4 or other genes functionally interact
during the normal cell cycle and how this pertains to cancer therapy. ATR activation is a
significant adaptive mechanism in cancer cells, and these studies could give us additional targets
to inhibit as cancer therapy along with inhibiting ATR. In addition, they could reveal genetic
backgrounds that might make ATR inhibition a particularly effective therapy.
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CHAPTER 2- THE ROLES OF MEC1 AND DBF4 IN PREVENTION OF DNA
REREPLICATION IN THE MEIOTIC RECOMBINATION CHECKPOINT
2.1 Introduction
DNA replication occurs early during meiosis and is necessary for the subsequent
formation of haploid gametes through two consecutive rounds of chromosome segregation.
Meiotic DNA replication is tightly regulated so that initiation occurs exactly once and at the
correct time during meiosis (95). Without checkpoint systems, errors such as DNA rereplication
can occur that can cause genome instability and gene amplification (96). CDK complexes are
central regulators of eukaryotic DNA replication initiation, both in the mitotic cell cycle (97)
and in meiosis (98-100). Our lab has previously discovered that meiotic expression of a
stabilized form of the B-type cyclin-CDK inhibitor Sic1 leads to DNA rereplication in
Saccharomyces cerevisiae (101). This is consistent with CDK preventing DNA rereplication
during the mitotic cell cycle by inhibiting the reformation of the pre-replicative complex
(97,102,103).
Meiotic DNA replication is followed by programmed recombination between
homologous chromosomes during prophase I in S. cerevisiae as well as most eukaryotes.
Recombination allows for the physical interaction of homologs, which is important for accurate
chromosome segregation during this division. Recombination also functions in transferring
genetic information between the parental chromosomes as a means of increased genetic
diversity. Spo11 creates a DSB that can then initiate the process of recombination (104,105), and
there are controls to ensure that each chromosome completes at least one recombination event
(106). Each DSB is processed to generate 3’-ssDNA overhangs that invade the homologous
duplex chromosome; this process is termed strand invasion (107,108). Without the meiosisspecific DNA recombinase Dmc1, strand invasion cannot proceed and extensive DNA resection
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results. DNA resection forms ssDNA and recombination intermediates that activate the meiotic
recombination checkpoint response that then prevents meiotic progression past prophase I
(109,110).
The meiotic recombination checkpoint pathway that is activated by deletion of DMC1
(dmc1Δ) is similar to DNA damage checkpoint pathways that function during the mitotic cell
cycle (111). Mec1 and its associated protein Ddc2, the ortholog of human ATR-interacting
protein (ATRIP), function in both pathways. A facilitator of Mec1 function, the Ddc1-Mec3Rad17 (“9-1-1”) complex, is also involved in both meiotic and mitotic checkpoint pathways
(24,111-116). The Dot1 methyltransferase is similarly involved in both pathways (117-119).
Rad53 and its mediator Rad9 (53,113,120-122) have not been found to be involved in the
meiotic recombination checkpoint (109,111,123). However, Rad53 and Rad9 are involved in
meiotic checkpoints in certain circumstances, including the response to HU, which depletes
nucleotide pools (124) and to DNA damage not induced by Spo11 (125,126). In the meiotic
recombination checkpoint, meiosis-specific proteins respond to recombination intermediate
structures and perform similar functions to Rad53 and Rad9 (110,123,127). These include Hop1,
Red1, and Mek1, components of the sister chromatid derived axial elements that are important
for proper meiotic recombination. Hop1 and Red1 are structural proteins (128,129), while Mek1
is a protein kinase similar in sequence to Rad53 (123,130,131). These proteins help to enforce
inter-homolog recombination during unperturbed meiosis and prevent inter-sister recombination,
thereby promoting normal chromosome segregation (130,132-136). Deletion of DMC1 activates
the meiotic recombination checkpoint where Red1 associates with the 9-1-1 complex and
facilitates Mec1 activation (137). Mec1 then phosphorylates Hop1, which is required for Mek1
activation (138). Active Mek1 prevents excessive recombination between sister chromatids and
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thereby maintains the checkpoint signal (139,140). Mek1 also halts meiotic progression in cells
displaying defective DSB repair (110,126,133).
The Brush lab has developed a system in which cells induced to undergo meiosis
(sporulation) experience DNA rereplication (101). This phenotype occurs when CDK activity is
deregulated through early meiosis-specific expression (via the HOP1 promoter) of SIC1∆PHA, an
HA-tagged Sic1 variant that lacks critical CDK phosphorylation sites necessary for Sic1
degradation (141). DNA rereplication does not occur in this system when the Sic1HA
phosphorylation sites are not altered, because HA-tagged Sic1 is subject to phosphorylation and
degradation, like normal Sic1. It was further found that deletion of DMC1 (dmc1Δ) activates a
response that prevents the DNA rereplication phenotype normally observed in the SIC1∆PHA
cells. This pathway was examined genetically by further mutating genes in the SIC1∆PHA dmc1∆
strain. If there was a return to the rereplication phenotype after gene mutation in the SIC1∆PHA
dmc1∆ background, it infers that the gene is necessary to prevent DNA rereplication after the
meiotic recombination checkpoint has been activated by the absence of DMC1.
2.2 Materials and Methods
2.2.1 Strains
Yeast strains used in this study are listed in Table 2.1. Generation of the HOP1prSIC1∆PHA strain was described previously (101). Most deletion mutant diploids were first
generated in haploids by homology-directed site-specific replacement with selectable markers
(142). PCR-amplification was performed from either a plasmid (143) or genomic DNA of a
mutant from the deletion set to generate the markers (144) (GE Dharmacon). Other mutants used
to create our diploid mutants in the W303 background were kindly provided by the following
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Strain
YGB495
YGB535
YGB604
YGB679
YGB758
YGB759
YGB788
YGB789
YGB866
YGB867
YGB934
YGB938
YGB966
YGB967
YGB1012
YGB1014
YGB1075
YGB1241
YGB1255

Relevant Genotype
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3
dmc1∆::kanMX4/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/”
mek1∆::kanMX4/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3
rad9∆::kanMX4/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3
dmc1∆::natR/”rad9∆::kanMX4/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3
mec1∆::LEU2/” sml1∆::kanMX4/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3
dmc1∆::natR/” mec1∆::LEU2/” sml1∆::kanMX4/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 mcm5bob1::HIS3/” sld3-38A-10his-13myc::kanMX/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/”
mcm5-bob1::HIS3/” sld3-38A-10his-13myc::kanMX/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/”
hta1-S129A::his3MX6/” hta2-S129A::TRP1/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/”
mek1∆::kanMX4/” rad54∆::TRP1/rad54∆::HIS3
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/”
dot1∆::kanMX6/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/”
hta1-S129A::his3MX6/” hta2-S129A::TRP1/”
dot1∆::kanMX6/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3
rad54∆::TRP1/rad54∆::HIS3
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 hta1S129A::his3MX6/” hta2-S129A::TRP1/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/”
dbf4∆::TRP1/” his3::PDBF4-dbf4-4A::HIS3/” sld3-38A10his-13myc::kanMX/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3 dmc1∆::natR/”
sml1∆::kanMX4/”
ura3-1/ura3-1::HOP1pr-SIC1∆PHA-URA3
DMC1/dmc1∆::natR dbf4∆::TRP1/” his3::PDBF4-dbf44A::HIS3/” sld3-38A-10his-13myc::kanMX/”

Table 2.1. Yeast strains.

Designation
SIC1∆PHA a
SIC1∆PHA dmc1∆ a,b
SIC1∆PHA dmc1∆ a
SIC1∆PHA dmc1∆
mek1∆
SIC1∆PHA rad9∆
SIC1∆PHA dmc1∆
rad9∆
SIC1∆PHA mec1∆
sml1∆
SIC1∆PHA dmc1∆
mec1∆ sml1∆
SIC1∆PHA mcm5bob1 sld3-38A
SIC1∆PHA dmc1∆
mcm5-bob1 sld338A
SIC1∆PHA dmc1∆
h2a-S129A
SIC1∆PHA dmc1∆
mek1∆ rad54∆
SIC1∆PHA dmc1∆
dot1∆
SIC1∆PHA dmc1∆
h2a-S129A dot1∆
SIC1∆PHA rad54∆
SIC1∆PHA h2aS129A
SIC1∆PHA dmc1∆
dbf4-4A sld3-38A
SIC1∆PHA dmc1∆
sml1∆
SIC1∆PHA dbf4-4A
sld3-38A
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researchers: SKY2939 (h2a-S129A) (145) by Stephen Kron (University of Chicago), YFL234
(dot1Δ) (118) by Marco Muzi-Falconi (Università degli Studi di Milano), and Y2359 and Y2573
(dbf4-4A, sld3-38A, and mcm5-bob1) (68) by Philip Zegerman (The Gurdon Institute, UK) and
John Diffley (The Francis Crick Institute, UK). Crossing was then used to establish these
mutations into our mutant background. The mutations were added into MATa cells and MATα
cells either containing the HOP1pr-SIC1∆PHA module already or added later, and then the two
cell types were mated. The SIC1∆PHA designation signifies that there is a single copy of the
HOP1pr-SIC1∆PHA element, but other designations signify that both copies have been altered.
PCR was used to confirm the gene mutations in all cases. Point mutants such as the mutant sld3
and dbf4 alleles were verified by DNA sequencing.
2.2.2 Cell Culture
For this project, yeast strains were incubated at 30°C. Induction of meiosis was carried
out by a synchronous sporulation starvation procedure (146). Yeast cells were first streaked onto
solid (2% (w/v) agar) YPG medium (1% (w/v) yeast extract, 2% (w/v) peptone, 3% (v/v)
glycerol). In some cases, when colonies were growing slowly on YPG we instead streaked onto
solid YPD medium (1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) dextrose). Plates were
incubated for 3-4 days, and then liquid YPD was inoculated with single colonies. Cultures were
incubated overnight then were used to inoculate liquid YPA (1% (w/v) yeast extract, 2% (w/v)
peptone, 2% (w/v) potassium acetate) at an OD600 of 0.2 and incubated for 16 hours. Cultures
were then normalized to the OD600 value of the strain with the lowest cell density and inoculated
into sporulation medium (0.3% (w/v) potassium acetate and 0.02% (w/v) raffinose supplemented
with leucine, arginine, and histidine each at 250 µM, tryptophan at 100 µM, and uracil at 50 µM).
Sporulation media cultures were incubated for 24 hours and aliquots were harvested at indicated
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time points for DNA content and protein analyses. All experiments included the SIC1∆PHA and
SIC1∆PHA dmc1∆ strains as positive and negative controls, respectively. Each experiment was
repeated independently at least three times.
Strains grown in a mitotic cell cycle time course were used as controls in several
experiments. Overnight cultures of MATa cells were brought to an OD600 of 0.2 and incubated
for two hours. Cultures were arrested in G1 by incubating for two hours with yeast mating
pheromone α-factor (Zymo Research) at a concentration of 2.5 µM in YPD. Then the media was
removed and cells were washed with sterile water to dilute the α-factor. Fresh YPD was added to
the cells and aliquots were taken every 15 minutes for DNA content and western blotting
analyses. For hydroxyurea (HU) treated controls, cells were arrested with α-factor as described
and released into 0.8X YPD with 0.2 M HU (MP Biomedicals).
2.2.3 DNA Content
Flow cytometry was used to measure DNA content. Aliquots from time courses were
immediately centrifuged, resuspended in 70% ethanol to fix the cells and then stored at 4°C. The
fixed cells were washed with 1 ml 50 mM Tris–HCl, pH 7.5, resuspended in 1 ml of the same
buffer, and 250 µg of RNase A was added. Samples were incubated at 37°C for 1 hour, and 250
µg of proteinase K was subsequently added to the samples and incubated at the same conditions.
Digested samples were incubated overnight at 4°C with 10X SYBR Green I (Molecular Probes).
Samples were briefly sonicated before analyzing with a FACSCanto II flow cytometer (BD
Biosciences) at the Microscopy, Imaging, and Cytometry Resources Core at Wayne State
University School of Medicine. WinMDI freeware was used to create DNA content histograms.
2.2.4 Protein
Samples of cells from time courses were centrifuged, media was aspirated, and cell
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pellets were stored at -70°C. For most experiments, an alkaline extraction method (147) was
used to denature whole-cell extracts. For experiments analyzing Rad53, a tricholoroacetic acid
bead beating method was performed (148). After protein extraction, samples were exposed to
SDS-polyacrylamide electrophoresis. For western blotting, the resolved proteins were transferred
to nitrocellulose (GE Healthcare). Primary antibodies included rat anti-α-tubulin (Serotec),
mouse anti-hemagglutinin (Covance), rabbit anti-yeast γ-H2A (kindly provided by Christophe
Redon and William Bonner, National Cancer Institute) (149), and rabbit anti-Rad53 (Abcam).
Signals were generated with IRDye 800-conjugated goat anti-rat (Rockland), Alexa Fluor 680
goat anti-rabbit (Invitrogen), or Alexa Fluor 680 goat anti-mouse (Invitrogen) secondary
antibodies. The Odyssey infrared imaging system (Li-Cor) was used to visualize reactive bands.
For the Rad53 autophosphorylation in situ assay, resolved proteins were transferred to PVDF
(Millipore) and analyzed as described (148).
2.3 Results
2.3.1 Mec1 and Mek1 Prevent DNA Rereplication during the Meiotic Recombination
Checkpoint
The Brush laboratory previously showed that deletion of HOP1 or RED1 restored DNA
rereplication in SIC1∆PHA dmc1Δ cells, indicating that they are each required for prevention of
DNA rereplication in our system. In these cases, DNA rereplication was robust, exhibited by the
generation of cells with DNA content reaching ~16C in some cases (150). Deletion of RAD17,
which encodes a 9-1-1 member, also results in a return to the rereplication phenotype in the
SIC1∆PHA dmc1Δ strain, indicating that RAD17 is required for suppression of DNA rereplication
in our system (101). Since the 9-1-1 complex is a critical activator of the Mec1-mediated DDR,
we hypothesized that Mec1 would also be involved in the meiotic recombination checkpoint. A
mec1∆ sml1∆ mutant was generated in the SIC1∆PHA dmc1Δ background, and DNA rereplication
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was observed in the SIC1∆PHA dmc1∆ mec1∆ sml1∆ cells. This phenotype was not due to sml1∆,
because SIC1∆PHA dmc1∆ sml1∆ cells did not display DNA rereplication (Figure 2.1).
Therefore, MEC1 is required for prevention of DNA rereplication in meiotic SIC1∆PHA dmc1∆
cells. Less robust DNA rereplication was observed in SIC1∆PHA dmc1∆ mec1∆ sml1∆ cells than
in SIC1∆PHA cells. Some of this effect may have been due to the absence of MEC1 and SML1
since SIC1∆PHA mec1∆ sml1∆ cells show slightly less rereplication than SIC1∆PHA cells (Figure
2.2). SIC1∆PHA expression was also probed by using an antibody against HA, and SIC1∆PHA
expression was found to be approximately equal between strains. SIC1∆PHA was expressed early
during meiosis in the four-hour time point and was not degraded by the 24-hour time point.
Therefore, differences in SIC1∆PHA expression cannot be the reason for the differences in DNA
rereplication observed between strains (Figure 2.1). HA expression was probed after every time
course, and the same pattern was seen in each experiment.
A SIC1∆PHA dmc1∆ mek1∆ strain was then examined for DNA rereplication. Similar to
deletion of MEC1, deletion of MEK1 also caused DNA rereplication in the SIC1∆PHA dmc1∆
background. RAD54 is involved in inter-sister repair during both meiosis and mitosis (151). It
was shown that dmc1∆ mek1∆ cells that are also rad54∆ and therefore incapable of completing
inter-sister repair progress through meiosis, but with slower dynamics (126,152). Therefore,
Mek1 has separate roles in preventing inter-sister repair and in preventing meiotic progression.
To determine whether the MEK1 function to suppress inter-sister repair or its function in
preventing meiotic progression was the reason for the phenotype detected in our system,
SIC1∆PHA dmc1∆ mek1∆ rad54∆ cells were examined. The rescue of DNA rereplication
observed in SIC1∆PHA dmc1Δ mek1Δ cells was not identified after the addition of rad54∆
(Figure 2.3). An increase in phosphorylated histone H2A (γ-H2A), a marker for DSBs (153), was
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Figure 2.1 MEC1 is essential for dmc1Δ-dependent prevention of SIC1∆PHA-induced DNA
rereplication. Strains were induced to undergo meiosis by performing a synchronous sporulation
protocol. Samples were taken for protein and DNA content at the indicated time points. Western
blotting was then performed to examine HA (Sic1∆PHA) and tubulin. Flow cytometry was
performed to observe DNA content. For all figures, 4C indicates diploid cells that have
experienced one round of DNA replication. Cells that have undergone DNA rereplication are
located to the right of the 4C peak.
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Figure 2.2 MEC1 is required for robust DNA rereplication in the SIC1∆PHA background.
Strains were induced to undergo meiosis by performing a synchronous sporulation protocol.
Samples were taken for protein and DNA content at the indicated time points. Western blotting
was then performed to examine HA (Sic1∆PHA) and tubulin. Flow cytometry was performed to
observe DNA content.
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Figure 2.3 MEK1 is essential for prevention of SIC1∆PHA-induced DNA rereplication when
the meiotic recombination checkpoint is activated by deletion of DMC1. Strains were
induced to undergo meiosis by performing a synchronous sporulation protocol. Samples were
taken for protein and DNA content at the indicated time points. Western blotting was then
performed to examine HA (Sic1∆PHA), γ-H2A, and tubulin. Flow cytometry was performed to
observe DNA content.
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observed in each strain. These data implied a persistence of DSBs throughout the meiotic time
course regardless of DMC1 or RAD54 status. RAD54 itself was not required for the DNA
rereplication phenotype (Figure 2.4). These data suggest that MEK1 inhibited DNA rereplication
because of its function in preventing inter-sister repair and maintaining the DSB-induced signal
rather than by halting DNA replication itself or halting meiotic progression.
2.3.2 γ-H2A and Dot1 Prevent DNA Rereplication during the Meiotic Recombination
Checkpoint
Mec1 and Tel1 phosphorylate H2A at serine 129 (γ-H2A), which promotes DSB repair
(56,57) and functions in the G1 DNA damage checkpoint (154,155). Since MEC1 was required
to prevent DNA rereplication in our system, we hypothesized that one of its major targets may be
as well. γ-H2A was generated in cells with wild type H2A (HTA1 and HTA2) regardless of
DMC1 status (see Figure 2.3). A SIC1ΔPHA strain was generated with serine to alanine mutations
in both HTA1 and HTA2 (h2a-S129A) so that the two H2A subunits could not be phosphorylated
at this position. Western blotting confirmed that these cells did not express γ-H2A (Figure 2.4
and Figure 2.5). Importantly, absence of γ-H2A led to DNA rereplication in SIC1∆PHA dmc1Δ
cells. Again, the rereplication phenotype was not as extensive as in SIC1∆PHA cells with regard
to total number of cells exhibiting >4C DNA or >~8C, but the DNA rereplication was welldefined and repeatedly observed (Figure 2.6). As a control, SIC1∆PHA h2a-S129A cells were also
shown to rereplicate their DNA with some cells clearly displaying >~8C DNA content (Figure
2.4).
It was further hypothesized that another integral gene involved in the G1 DNA damage
response, DOT1 (118,119), would be required for the meiotic response to DNA rereplication in
our system. DOT1 encodes a histone methyltransferase that catalyzes methylation of histone H3
at lysine K79 (156-158) and has been shown previously to be involved in the meiotic
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Figure 2.4 Deletion of RAD54 or mutation of H2A does not affect the SIC1∆PHA-induced
DNA rereplication phenotype. Strains were induced to undergo meiosis by performing a
synchronous sporulation protocol. Samples were taken for protein and DNA content at the
indicated time points. Western blotting was then performed to examine HA (Sic1∆PHA) and
tubulin. Flow cytometry was performed to observe DNA content.
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Figure 2.5 SIC1ΔPHA dmc1Δ h2a-S129A cells do not express γ-H2A during the meiotic time
course. Strains were induced to undergo meiosis by performing a synchronous sporulation
protocol. Samples were taken for protein at the indicated time points. Western blotting was then
performed to examine γ-H2A and tubulin.
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Figure 2.6 γ-H2A and DOT1 are required for dmc1Δ-dependent inhibition of SIC1∆PHAinduced DNA rereplication. Strains were induced to undergo meiosis by performing a
synchronous sporulation protocol. Samples were taken for protein and DNA content at the
indicated time points. Western blotting was then performed to examine HA (Sic1∆PHA) and
tubulin. Flow cytometry was performed to observe DNA content.
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recombination checkpoint response (117). In a similar manner as h2a-S129A, an intermediate
amount of DNA rereplication was observed in SIC1∆PHA dmc1Δ dot1∆ cells. Interestingly,
combination of the dot1∆ and h2a-S129A mutations in the SIC1∆PHA dmc1Δ background did not
enhance the amount of DNA rereplication compared with either single mutant (Figure 2.6).
These data suggest that γ-H2A and Dot1 operated in the same pathway to prevent DNA
rereplication in SIC1∆PHA dmc1Δ cells.
2.3.3 Dbf4 and Sld3 Phosphorylation is Required for Prevention of DNA Rereplication
During the Meiotic Recombination Checkpoint
Rad53 has not been shown to be involved in the meiotic recombination checkpoint, but it
can be activated by genotoxic stress during meiosis (124-126). With Rad53 being a crucial
downstream signaling kinase in the Mec1 pathway during the mitotic cell cycle (48) and Mec1
being essential for the meiotic checkpoint response to DNA rereplication (Figure 2.1), we
hypothesized that Rad53 would be involved in prevention of DNA rereplication as well. With
these two pieces of conflicting evidence, it was elected to determine whether RAD53 was active
in the meiotic checkpoint that prevents DNA rereplication in our system. Like MEC1, RAD53 is
an essential gene, but rad53Δ cells are viable when SML1 is also defective (41). Surprisingly,
SIC1∆PHA rad53∆ sml1-1 cells did not exhibit DNA rereplication (150). This makes it
impossible to identify genetically whether RAD53 itself is required for the dmc1∆-induced
meiotic checkpoint response in preventing DNA rereplication since RAD53 deletion prevents
DNA rereplication in the SIC1∆PHA background.
So we elected to examine RAD9, which encodes a mediator of Rad53 activation
(121,159,160). Importantly, rad9∆ did not prevent DNA rereplication in the SIC1∆PHA
background (150). SIC1∆PHA dmc1∆ rad9∆ cells did not exhibit DNA rereplication, indicating
that RAD9 was not required for suppression of DNA rereplication in SIC1∆PHA dmc1Δ cells
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(Figure 2.7). This infers that RAD9 was not required for this checkpoint response to DNA
rereplication. Since the function of RAD53 could not be studied through gene deletion, genes that
function downstream of Rad53 in the mitotic checkpoint response were studied to investigate
whether they also function in the meiotic checkpoint response to DNA rereplication. Rad53
responds to DNA damage or replication fork stalling during S phase of the mitotic cell cycle and
is activated to catalyze phosphorylation of Dbf4 and Sld3, which prevents firing of late origins
(66,68). Two different mutant strains were used to determine whether this process could be
involved in the meiotic response to DNA rereplication in our system. One strain contains mutant
alleles of both DBF4 and SLD3, with mutations in important phosphorylation targets of Rad53.
SIC1∆PHA dmc1∆ cells containing the mutant dbf4-4A and sld3-38A alleles demonstrated DNA
rereplication (Figure 2.8), indicating that phosphorylation of Dbf4 or Sld3, or both proteins, was
required for full prevention of DNA rereplication. These cells appeared to rereplicate their DNA
to a lesser extent than SIC1∆PHA cells in that they did not exhibit >~8C DNA content, as in the
case of SIC1∆PHA dmc1∆ h2A-S129A cells. In SIC1∆PHA dbf4-4A sld3-38A cells, robust DNA
rereplication was detected with some cells displaying >~8C DNA content, indicating that the
phosphorylation site mutations themselves were not responsible for limiting DNA rereplication
(Figure 2.9). The second mutant strain contains the sld3-38A allele together with mcm5-bob1, a
mutant allele that bypasses the essential function of DBF4 (161). DNA rereplication was not
recovered after addition of mcm5-bob1 sld3-38A alleles into SIC1∆PHA dmc1∆ cells (Figure 2.8).
As a control, it was confirmed that the mcm5-bob1 allele alone did not prevent DNA
rereplication in the SIC1∆PHA background (150). Previous mitotic cell cycle results indicated that
cells with mutated Dbf4 phosphorylation sites behaved similarly to cells with the mcm5-bob1
allele. Our results displayed a clear difference between the two strains, but certain experimental
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Figure 2.7 Rad53 is not activated during the dmc1∆-dependent meiotic recombination
checkpoint. A, Strains were induced to undergo meiosis by performing a synchronous
sporulation protocol. Samples were taken for protein and DNA content at the indicated time
points. Western blotting was then performed to examine HA (Sic1∆PHA) and tubulin. Flow
cytometry was performed to observe DNA content. B, Western blotting for Rad53 (top panel)
and Rad53 autophosphorylation in situ (32P-Rad53, middle panel) were performed using the
same samples from the synchronous sporulation experiment shown in A. Ponceau S staining
(bottom panel) was used to determine total protein loading. Vegetative SIC1ΔPHA dmc1Δ
(RAD53) and rad53Δ sml1-1 (rad53Δ) diploids were treated with HU for the indicated times as
positive and negative controls, respectively.
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Figure 2.8 Phosphorylation sites on Sld3 and/or Dbf4 that are normally targeted by Rad53
are required for suppression of DNA rereplication. Strains were induced to undergo meiosis
by performing a synchronous sporulation protocol. Samples were taken for protein and DNA
content at the indicated time points. Western blotting was then performed to examine HA
(Sic1∆PHA) and tubulin. Flow cytometry was performed to observe DNA content.

'()*&+,

&

'(&

/)0-01(

!"#$ %&'(
)*+,-,(&./)0-01(

!"#$ %'(&
$

#!&-.

!&

%

#!

$

!&

%

#!&-.

!"

#$%

#$%

!"

$

$

!&

!&

%

%

#!&-.

#!&-.
/0"

28

#" !"

%"

#" !"

%"

/0"

Figure 2.9 Mutations in DBF4 and SLD3 phosphorylation sites or mutations in MCM5 and
SLD3 do not block DNA rereplication induced by SIC1∆PHA. Strains were induced to
undergo meiosis by performing a synchronous sporulation protocol. Samples were taken for
protein and DNA content at the indicated time points. Western blotting was then performed to
examine HA (Sic1∆PHA) and tubulin. Flow cytometry was performed to observe DNA content.
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factors may cause the difference seen between our meiotic studies and previous mitotic cell cycle
studies (see Discussion). These data imply that Dbf4 phosphorylation was sufficient in order to
prevent DNA rereplication, at least with the addition of the mcm5-bob1 allele. Notably, either
Dbf4 or Sld3 phosphorylation alone can help to prevent late origin firing in mitotic S phase
(66,68). In conclusion, Rad53 phosphorylation targets in the mitotic cell cycle also functioned to
prevent meiotic DNA rereplication in our system. These seemingly incongruent results show that
a mediator of Rad53 activity, Rad9 is not necessary for prevention of DNA rereplication, yet
Dbf4 and/or Sld3 phosphorylation sites that are normally targeted by Rad53 are required for
prevention of DNA rereplication in our system. The RAD9 data shows that Rad53 is probably not
involved, however the Dbf4 and Sld3 phosphorylation site data indicates that Rad53 may be
involved in prevention of DNA rereplication in our system. Therefore, Rad53 enzymatic activity
during meiosis was directly probed in our system.
2.3.4 Rad53 is not Activated during the Meiotic Recombination Checkpoint in Response to
DNA Rereplication
Rad53 autophosphorylates in a Mec1-dependent manner to increase its kinase activity.
One method to investigate Rad53 activity is by inspecting Rad53 species with reduced
electrophoretic mobility, which is indicative of its phosphorylation and activation. This can be
accomplished via western blot; however, a more sensitive method is to examine Rad53
autophosphorylation in situ (162). Both methods were performed to assess Rad53
phosphorylation and activation. Using the immunoblot method, a Rad53 phospho-isoform was
only detected in HU-treated mitotic cells that were used as a positive control (Figure 2.7). Using
the Rad53 autophosphorylation in situ method, there was a slight Rad53 activation at the 24 hour
time point after sporulation was induced in the SIC1ΔPHA, SIC1ΔPHA dmc1Δ, and SIC1ΔPHA
dmc1Δ rad9Δ strains. However, this activation was negligible compared to HU-induced Rad53
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activation in mitotic cells (Figure 2.7). While the Rad53 activation in SIC1ΔP dmc1Δ cells seems
slightly higher than in SIC1ΔP cells, the SIC1ΔPHA dmc1Δ rad9Δ cells do not exhibit a
heightened activation compared to SIC1ΔPHA cells (Figure 2.7). Therefore, it is improbable that
this degree of activation could have been responsible for the checkpoint especially because
heightened Rad53 activation was not observed in the checkpoint-proficient SIC1ΔPHA dmc1Δ
rad9Δ cells. It is also possible that aside from the meiotic recombination checkpoint, a general
persistence of DSBs and DNA damage accumulated over time in SIC1ΔPHA dmc1Δ cells led to a
low level of Rad9-dependent Rad53 phosphorylation.
2.4 Discussion
Previously, it was found that DMC1 deletion halts DNA rereplication induced by
stabilization of Sic1. Further deletion of RAD17 rescued the DNA rereplication phenotype (101).
Also, further deletion of RED1, HOP1, or MEK1 from the SIC1ΔPHA dmc1Δ genetic background
resulted in a return to the rereplication phenotype (150). Genes involved in meiotic and mitotic
cell cycle checkpoints that were hypothesized to be involved in prevention of DNA rereplication
were investigated using this system. It was discovered that MEC1 and other upstream
components of the checkpoint were required to prevent DNA rereplication. However, there was
no evidence that certain downstream effectors that regulate meiotic progression were involved in
this system. Strains containing mutations in genes involved in preventing DNA replication in the
mitotic cell cycle were also examined. Phosphorylation of Dbf4 and/or Sld3 was required for full
prevention of DNA rereplication in our system. Intriguingly, these data suggest that effectors are
phosphorylated in a Rad53-independent manner.
There were clear differences in the quantity of DNA rereplication recovery in SIC1∆PHA
dmc1Δ cells depending on which additional gene was deleted or mutated (Figure 2.10). It is
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Figure 2.10 DNA rereplication quantified in each strain. A) The 24-hour time point sample
from each strain was analyzed, and the gating function in WinMDI software was used to quantify
the number of cells exhibiting more than 4C DNA content. The gating was kept constant
between strains in each experiment. B) The number of cells exhibiting >4C DNA content in each
strain out of 20,000 total cell counts is displayed on the y-axis. Data points from strains that fit
our criteria for DNA rereplication are displayed as filled circles, and data points from strains that
did not fit our criteria for DNA rereplication are displayed as open circles.
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noted that the SIC1∆PHA dmc1∆ rad9∆ strain showed minor DNA rereplication in three
experiments, however, the majority of the experiments showed levels of DNA rereplication
comparable to the SIC1∆PHA dmc1∆ strain. The SIC1∆PHA dmc1∆ dbf4-4A sld3-38A strain
showed low levels of DNA rereplication in two of the six experiments. In these two experiments,
meiotic progression in all strains was slow. In conclusion, strains displaying lower levels of
DNA rereplication were more prone to experimental variability.
Inter-experimental variability makes it problematic to be conclusive about these
differences, but there were clear trends in regards to the mutant pathways involved. For example,
removal of proteins that prevent both inter-sister repair and meiotic progression, such as Mek1,
resulted in robust DNA rereplication with a significant number of cells containing >~8C DNA
content. These experiments imply that Mek1 functions in preventing inter-sister repair, and
subsequently retaining the checkpoint signal originating from unrepaired DSBs, to prevent DNA
rereplication in our system. It does not appear that the Mek1 functions in preventing DNA
replication or halting meiotic progression contribute to meiotic prevention of DNA rereplication
in our system. In contrast to this data, mutation of genes to abolish H2A or Dbf4 and Sld3
phosphorylation resulted in fewer cells exhibiting >~8C DNA content. This difference may be
occurring because the degree of DNA rereplication is restricted by unrepaired and resected
DSBs, although approximately equal γ-H2A staining was observed in the different strains
regardless of checkpoint status. It could also be the case that more than a single checkpoint
mechanism is involved in preventing DNA rereplication during meiosis, and only one is absent
in some strains such as in SIC1∆PHA dmc1Δ dbf4-4A sld3-38A cells. In this way, perhaps the
meiotic recombination checkpoint pathway in our system only controls a subset of origins.
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Regardless, the data clearly reveal that the DNA replication machinery can be targeted and
inhibited by the meiotic recombination checkpoint.
The pathway that prevents DNA rereplication during the meiotic recombination
checkpoint shares several components with mitotic cell cycle DDR checkpoint mechanisms.
Mec1, Rad17, and presumably the entire 9-1-1 complex were required for prevention of DNA
rereplication in our system. Notably, DNA rereplication during the mitotic cell cycle stimulates a
Mec1- and Rad17-dependent checkpoint response that halts further DNA rereplication (163).
Both MEC1 and RAD17 were essential for prevention of DNA rereplication in our system.
Interestingly, slightly less DNA rereplication was observed upon deletion of MEC1 and SML1
from SIC1∆PHA dmc1Δ cells when compared with SIC1∆PHA dmc1Δ strains lacking genes such
as MEK1, especially with regard to cells with >~8C DNA content. It is also possible that deletion
of MEC1 and SML1 had a minor impact on DNA rereplication in SIC1∆PHA cells. It was reported
that dmc1Δ mec1-1 cells progress through meiosis with unrepaired DSBs (111). As proposed
above, persistent unrepaired DSBs may influence the amount of DNA rereplication in our
system. The function of Tel1 in preventing DNA rereplication during the meiotic recombination
checkpoint was not examined. Tel1 is a Mec1-related PIKK that is involved in DDR pathways
including the meiotic recombination checkpoint response (164-166). Tel1, as is the case with
Mec1, catalyzes Hop1 phosphorylation that is required for Mek1 activation (138). Perhaps the
DNA rereplication phenotypic difference between SIC1∆PHA dmc1Δ mec1Δ sml1Δ and
SIC1∆PHA dmc1Δ mek1Δ cells (detected even though Mek1 normally functions downstream of
Mec1) is because of Tel1’s function. Alternatively, downstream effectors of Mec1, besides
Mek1, may be promoting DNA rereplication.
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The Mec1 binding partner Ddc2 associates with RPA bound to ssDNA and assists with
Mec1 activation (12). RPA-bound ssDNA would be abundant in dmc1Δ cells because of highly
resected DSBs created by Spo11 (109). Active Mec1 can then phosphorylate H2A to form γH2A, which was found to be required for full prevention of DNA rereplication. DOT1, which
encodes the enzyme that generates H3meK79, was also required for prevention of DNA
rereplication in our system. γ-H2A was abundant and H3meK79 was likely abundant (158) in
SIC1∆PHA cells that displayed DNA rereplication. These two histone modifications were
necessary but not sufficient for the full checkpoint response to DNA rereplication. In mitotic
cycling cells, particularly during the G1 DDR, these modifications and Rad6-Bre1 mediated
histone H2B ubiquitylation required for H3meK79 are vital for Rad9 recruitment and Rad53
activation (118,154,155). Neither RAD9 nor RAD53 were required and neither seemed to be
involved in prevention of DNA rereplication during the meiotic recombination checkpoint
response. It could be possible that Rad53 is activated by a mechanism that cannot be detected by
our methods, but this seems improbable. In fact, these results are consistent with the multiple
findings that the Rad9-Rad53 axis is not involved in the meiotic recombination checkpoint that
prevents pachytene exit and halts progression through meiosis (109,111,123). Intriguingly,
residues in Dbf4 and/or Sld3 that are typically targets of phosphorylation by Rad53 during the
mitotic cell cycle and serve to prevent late origin finding (66,68) function to prevent DNA
rereplication during the meiotic recombination checkpoint. However, there was a slight
disagreement with mitotic cell cycle observations in regards to the strain that carries the mcm5bob1 allele, which eliminates the requirement for the DDK protein kinase in DNA replication
initiation (161). This allele did not substitute for the dbf4-4A mutant allele as it was shown
previously in the mitotic cell cycle studies (68). This difference could reflect fundamental
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differences in regulation of DNA replication during the mitotic cell cycle and meiosis, or it could
be because of lowered CDK activity in SIC1∆PHA cells.
Taken together, our results suggest that a response to DNA rereplication during the
meiotic recombination checkpoint involves a protein kinase that is activated in a similar manner
and has functions similar to those of Rad53 during the DDR in the mitotic cell cycle (see Figure
2.11). Mek1 would be an obvious candidate for this kinase activity since it has structural
similarity to Rad53 and it is expressed only during meiosis (123,130,131). However, our data
shows that Mek1 is required for prevention of DNA rereplication because of its functions in
preventing inter-sister repair and not because of a function in preventing DNA replication.
Furthermore, a peptide-based study looking at yeast kinase phosphorylation site specificity
placed Rad53 and Mek1 into the same cluster, but the two kinases are not closely related and
display clear differences in their extent of specificity (167). These data indicate that Mek1 is
unlikely to be responsible for Dbf4 and Sld3 phosphorylation during the meiotic recombination
checkpoint. Dun1 is another kinase with physical similarity to Rad53 and functions downstream
of Rad53 to regulate transcription and dNTP levels after a challenge with genotoxic stress
(53,168). However, biochemical studies propose different substrate specificities between the two
enzymes (169-171). A comprehensive analysis of transcriptional regulation after DNA damage
also indicates differential targeting by Rad53 and Dun1 (172). Therefore, there is no evidence to
demonstrate that Mek1 or Dun1 would phosphorylate the same sites as Rad53 in Sld3 and Dbf4,
suggesting that a separate kinase operates during meiosis that is similar in function to Rad53 and
can prevent DNA replication initiation. ATR can catalyze Dbf4 phosphorylation upon replication
stress or ionizing radiation, and this phosphorylation is important for the prevention of
rereplication during the mitotic cell cycle (94). A mechanism where Mec1 bypasses Rad53
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Figure 2.11 The proposed pathway that operates to prevent DNA rereplication when the
meiotic recombination checkpoint is activated. Mec1, Mek1, Dbf4, and Sld3 operate in the
dmc1∆-induced meiotic recombination checkpoint to prevent rereplication arising from
Sic1∆PHA. Also shown are the functions of Mek1 in normal cells. See discussion for the possible
kinases responsible for catalyzing Dbf4 and Sld3 phosphorylation.
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function and directly catalyzes Dbf4 and/or Sld3 phosphorylation could be involved in the
meiotic recombination checkpoint.
Since small amounts of rereplication can cause gene amplification (96), it is proposed
that rereplication could be an initiating factor in carcinogenesis. However, studying rereplication
in human cells is difficult since it usually results in extensive DNA damage that inevitably leads
to cell death. Methods to bypass the rereplication checkpoint lead to apoptosis or senescence
(173). Based on this concept, it has been proposed to induce DNA rereplication as cancer
therapy. It was found that inducing rereplication caused apoptosis in cancer cells but not in an
immortalized non-cancer cell line (174). Perhaps human orthologs of some proteins discovered
to be essential for prevention of DNA rereplication in our system could be targets for inhibition
as cancer therapy. Perhaps ATR inhibitors induce rereplication in cancer cells, and this is one
mechanism by which ATR inhibitors are effective.
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CHAPTER 3- SYNTHETIC GENETIC INTERACTIONS BETWEEN THE DNA
DAMAGE RESPONSE AND TRANSCRIPTION OR REPLICATION MACHINERIES
3.1 Introduction
3.1.1 Synthetic Genetic Interactions and their Role in Cancer Treatment
An important method to study gene function and how genes fit into pathways is by
analyzing phenotypes caused by the deletion of genes. This can be extended to studying the
deletion of two genes at once. Synthetic genetic interactions occur when the deletion of either of
two genes on their own does not cause a significant loss of fitness but when both genes are
deleted concurrently, a synergistic loss of fitness (synthetic sickness) or inviability (synthetic
lethality) occurs. Synthetic sickness is by definition a fitness defect that is greater than a
multiplicative effect of the fitness defect of each gene deletion on its own. In functional terms,
the deletion of one gene creates an intracellular environment that can only be handled by the
other gene product. If the second gene is deleted, the cell cannot deal with the environment and a
loss of fitness occurs (175). In many cases, synthetic genetic interactions can suggest that the
genes function in related pathways. When studying genes involved in the DDR, one gene
deletion may cause enhanced DNA damage that can only be processed in the presence of the
other gene. When the DDR gene is also deleted, there is a buildup of DNA damage that causes
lethality or reduced fitness.
The concept of synthetic lethality is important in the treatment of cancer in order to
establish what combination treatments may be effective and what treatments will selectively kill
cancer cells while sparing normal cells. This has been shown definitively in the treatment of
BRCA1 or BRCA2 mutated breast cancers with (poly ADP ribose polymerase) PARP inhibitors.
PARP is a family of proteins involved in several mechanisms but most importantly the base
excision repair pathway that repairs ssDNA damage (176). One theory is that when a PARP
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inhibitor is administered, ssDNA damage cannot be effectively repaired, so when the replication
machinery encounters this damage, the ssDNA damage is converted into a DSB. This damage
can be repaired in cells with functional DSB repair pathways, but in cancer cells with aberrant
DSB repair such as in BRCA1/2 mutated cancers, this damage cannot be repaired, which
subsequently causes apoptosis (177). PARP inhibitors are also theorized to trap PARP at
locations of damage, resulting in stalled replication forks, which ultimately leads to DSB
formation. This damage can be repaired in normal cells, but cancer cells with dysfunctional
BRCA genes cannot repair the damage and succumb to cell death (178). ATM or RAD51
mutations also confer an increased sensitivity to PARP inhibition (179).
A more recent example of synthetic lethality is in the treatment of mismatch repairdeficient solid tumors with an anti-PD-1 antibody. PD-1 functions in the immune checkpoint to
negatively regulate the immune response, so blocking PD-1 unleashes the immune system to
attack and kill cancer cells. Cancer cells with mismatch repair deficiency contain a large
proportion of neoantigens, which makes them more recognizable to the immune system, and
therefore more susceptible to anti-PD-1 antibody treatment (180). Mutations in genomic
instability genes are commonly seen in the early stages of carcinogenesis (181-183), which then
predisposes cells to gain further mutations and leads to transformation. Genes that synthetically
interact with these mutated genomic instability genes could be good targets for drug inhibition
since cancer cells should be more sensitive to treatment than normal cells. Also, since mutation
of genomic instability genes is an early event, there should be less heterogeneity with this
mutation between cells. As a result, most cancer cells should be sensitive to treatment.
One well established synthetic genetic interaction is between ATR/MEC1 and a related
PIKK, ATM/TEL1. There is a synergistic sensitivity of mec1 tel1 yeast double mutant strains to
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DNA damaging drugs (165). Human cancer cells that have dysfunctional ATM are
hypersensitive to ATR inhibitors (184,185), and siRNA that targets ATM sensitizes cells to ATRi
(186), both indicating a synthetic sick effect between ATR and ATM in human cancer cells. This
indicates synthetic genetic interactions can be conserved between budding yeast and higher
eukaryotes. A number of other cell cycle and DNA repair gene deficiencies have been found to
induce synthetic lethality with ATR inhibitors, including ERCC1 (187), XRCC1 (188), CDC25A
(189), and TP53 (184,190). Mutations in a subunit of the SWI/SNF chromatin-remodeling
complex, ARID1A, also induced synthetic lethality with an ATR inhibitor (186).
Synthetic genetic interactions are most easily studied in yeast because of the genetic
malleability of the model system, the fast doubling time, low cost, relatively small genome, and
ease of performing high-throughput screens. Most major signaling pathways, including the DDR
pathways, are highly conserved from yeast to humans (191). Some studies indicate that synthetic
genetic interactions are poorly conserved between yeast and higher eukaryotes (192-194).
However, others show that synthetic genetic interactions are highly conserved between yeast and
higher eukaryotes (195-199).
A synthetic genetic array (SGA) is a high-throughput method of examining synthetic
genetic interactions using robotic manipulation of yeast strains. A haploid strain with a gene
mutation of interest is mated with haploid strains from the gene deletion library, which consists
of ~5000 strains each with a single gene deletion. Heterozygous diploid double mutants are then
sporulated to produce haploids. Double mutant haploids are then selected using selection media
and colony size is measured (200,201). If the colony size, which is indicative of overall fitness, is
smaller than what would be expected by multiplying the effects of the two single gene deletions,
a negative synthetic genetic interaction can be inferred (202). Negative genetic interactions are
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especially important because they predict functional interactions that tend to interrupt redundant
pathways (203,204). SGAs have been performed using many different combinations of nonessential gene deletions (200,203). Advances in technology are now allowing the study of
essential genes via SGA. This is done by using conditionally down-regulated genes or by
studying hypomorphs (205,206). A SGA screen using a mec1 null strain performed in
collaboration with researchers at University of Toronto uncovered genes involved in
transcriptional regulation, including subunits of the Mediator complex, and genes involved in
DNA replication and repair (see Results).
3.1.2 Transcriptional Regulators and their Role in Cancer
As described further in the results section, a SGA screen was conducted using the mec1∆
strain and known and novel genetic interactions were revealed. Processes related to those
interactions are described here. Transcription is a tightly regulated process that mediates protein
levels in the cell. RNA polymerase II is responsible for transcription of mRNA and some noncoding RNA. The Mediator complex is a crucial component of transcriptional regulation because
it serves as physical communication between gene-specific regulatory factors and the RNA
polymerase II complex (207-209). Notably, the Mediator complex is highly conserved from
yeast to humans. It is made up of more than 20 subunits that are divided into four modules. The
head and middle modules interact directly with RNA polymerase II, the tail module interacts
directly with transcription factors, and the detachable kinase module can phosphorylate RNA
polymerase II in order to repress transcription (210,211). The Mediator complex is not only
involved in initiation of transcription, but also elongation and termination (212).
Many subunits of the Mediator complex have been associated with cancer. Mediator
complex subunit overexpression has been linked to breast, prostate, and colon cancers (213). One
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study looked at Mediator subunit expression of all subunits in osteosarcoma cell lines and
compared them to a normal osteoblast cell line. In general, subunits in the head module were
overexpressed and subunits in the kinase module were underexpressed in the cancer cells.
Interestingly, the MED20 subunit shows ~20 fold overexpression in the cancer cells (214).
MED9 and MED20 showed alterations in patient samples of several cancer types. MED20
amplification occurred in ~17% of breast cancer patient samples (215), ~7% of prostate cancer
samples (216), and ~4% of lung adenocarcinoma patients (217). MED9 was amplified in ~17%
of breast cancer patient samples (215) and was deleted in two of twelve breast adenoid cystic
carcinoma samples examined (218).
MED19 expression was higher in bladder cancer tissue than in paired normal tissue and
was associated with histopathological grade. Knockdown of MED19 caused tumor cell growth
inhibition in vitro and in vivo (219). MED19 was overexpressed in laryngocarcinoma patient
samples compared to normal tissue, and knockdown of MED19 in a laryngeal carcinoma cell line
caused growth inhibition in vitro and in vivo (220). Similarly, MED19 was knocked down in
prostate cancer cell lines and caused decreases in proliferation and migration. MED19 was
shown to be involved in upregulation of genes involved in cell cycle, cell proliferation, and
epithelial to mesenchymal transition (221). Overexpression of Mediator subunits in cancer cells
suggests possible oncogenic properties of certain Mediator subunits in certain malignancies.
Interestingly, other Mediator subunits may be acting as tumor suppressors. Loss of MED12 has
been associated with an epithelial to mesenchymal transition phenotype and tumor cell resistance
to multiple small molecule inhibitors used in cancer therapy, including ALK, EGFR, BRAF, and
MEK inhibitors (222,223). Mutations in the MED12 subunit were found to occur in 67% of
uterine leiomyoma, a benign tumor (224). When these mutations were created in a mouse model,
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it caused the mice to develop lesions consistent with leiomyoma. They found that the mutation
acted in a dominant fashion to increase genomic instability (225).
Several Mediator subunits were shown to be essential for acute myeloid leukemia (AML)
cell proliferation and knockdown of these subunits resulted in differentiation of leukemic blasts
(226). A novel inhibitor of the CDK8 kinase subunit of the Mediator complex has recently been
developed as a therapy for AML. The inhibitor was found to reduce tumor growth in a xenograft
mouse model (227). This indicates that certain Mediator subunits may be viable targets in the
treatment of certain cancers, such as AML.
The Mediator complex and BRD4, a member of the bromodomain and extraterminal
domain (BET) family, were found to co-occupy chromatin at super-enhancers, where high levels
of transcriptional cofactors are bound to large enhancer regions. An inhibitor of the BET family
(BETi), which is thought to globally suppress transcription, was found to evict Mediator from
super-enhancers of genes that promote carcinogenesis, such as MYC (226,228). Prolonged
binding of the MED1 subunit of the Mediator complex to chromatin was shown to be a
resistance mechanism to BETi (229). This inhibitor and a structurally distinct BETi were also
found to synergize with ATR inhibitors in Myc-induced lymphoma cell lines and a syngeneic
tumor transplant mouse model (230). If general transcriptional inhibitors synergize with ATR
inhibitors, then inhibition of Mediator complex subunits may be synergistic with inhibition of
ATR. The Mediator complex has an enormous number of subunits and not all of them are
essential, which would make it less likely that inhibition of a non-essential subunit would
produce toxicity towards normal cells. Also, specific subunits have been shown to be necessary
for the downstream effects of certain signaling pathways. For example, MED12/Srb8 and
MED13 are crucial for the activation of WNT signaling, a pathway that is dysregulated in a
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variety of cancers (231). If a specific inhibitor of MED12 or MED13 were developed, this could
inhibit WNT signaling without affecting other essential signaling pathways, which may result in
minimal adverse effects.
Transcriptional regulation has been linked with DNA damage in several pathways. An
important endpoint of the DDR is transcriptional regulation. An example of which is the p53
tumor suppressor, which is activated in response to DNA damage and subsequently works as a
transcription factor to increase transcription of a number of genes, including those involved in
DNA repair (232). In yeast, Mec1 responds to DNA damage by activating downstream
transcription factors, which then regulate transcription (233,234). In response to the DNA
alkylating agent, methyl methanesulfonate, Mec1 regulates the transcription of more than 600
genes through the activation of at least nine different transcription factors. As discussed earlier,
Mec1 is involved in resolving conflicts between transcription and replication machineries by
evicting transcription machineries and by resolving stalled replication forks (42,62). Another
connection between transcription and DNA damage is transcription-coupled DNA repair. DNA
damage can often interfere with the progression of the transcription machinery. The RNA
polymerase machinery can mediate recruitment of DNA repair proteins to the damage, which
perform transcription-coupled DNA repair so that transcription can resume (235).
3.1.3 Genes Involved in DNA Replication and Repair and their Role in Cancer
A central component of DNA replication is DDK, composed of DBF4 and CDC7, which
is essential for origin firing. The DDK complex is associated with cancer in several ways. DDK
is overexpressed in many tumor cells and DDK overexpression was correlated with loss of p53
in primary breast cancers, indicating that DDK overexpression may be a common phenomenon
in human cancers (236-243). Overexpression of DBF4 is correlated with poor prognosis in
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cutaneous melanoma patients (244). CDC7 overexpression in lung adenocarcinoma is correlated
with worse survival (245). Similar to the dependence of cancer cells on the ATR pathway to
avoid apoptosis, it is thought that cancer cells can also become dependent on DDK (246).
RAD18, which is involved in translesion synthesis, and RAD54, which is involved in
homologous recombination, are synthetic lethal in chicken cells (247). DDK is involved in the
translesion synthesis pathway (80), and could be a target to inhibit in BRCA1/2 mutant cancer
cells that have defective homologous recombination.
Interestingly, siRNA inhibition of DDK in HeLa cells caused p53-independent apoptosis,
while primary fibroblasts experienced p53-dependent cell cycle arrest (248). DDK is associated
with chemoresistance and higher frequency of mutations (245). Selective inhibitors of DDK have
been developed as anti-cancer agents. The rationale behind their use is that inhibition of DDK
should prevent phosphorylation of the MCM helicase and thereby prevent DNA replication. If
there is no replication fork, the DDR cannot sense a problem and therefore is not activated. DNA
damage then builds up and mitotic catastrophe occurs, eventually resulting in cell death (249).
PHA-767491 is a DDKi that was found to prevent MCM2 phosphorylation and induce DSBs.
CHK1 was not activated, indicating that the replication stress checkpoint was not activated.
Tumor growth inhibition and few side effects were seen in a mouse xenograft model of AML
(250). PHA-767491 was also found to inhibit glioblastoma cell line proliferation and trigger
apoptosis. It was further found to inhibit migration and invasion, which makes this drug
promising at reducing metastasis (251). PHA-767491 was found to synergize with 5-fluorouracil
in hepatocellular carcinoma cells, and the combination treatment caused more apoptosis than
either single drug alone (252). However, PHA-767491 has off-target effects on CDK9 (250).
Another DDKi, XL-413, was seen to be more specific for the DDK complex. Treatment caused
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cell cycle arrest in Colo-205 cells and tumor growth inhibition in a Colo-205 mouse xenograft
model (253). However, another study found that XL-413 was effective in Colo-205 cells but had
little effect on cell viability in the other seven cell lines they tested. They found that PHA767491 and XL-413 had similar activity on purified DDK, indicating that XL-413 may have low
bioavailability in most cell lines (236). XL-413 was previously used in clinical trials; however,
trials were suspended because of an “unfavorable pharmacologic profile” (SEC Research and
Collaboration Agreements December 31, 2012). There are several novel CDC7 inhibitors that
have been found to be selective and potent in vitro (254,255). There are also clinical trials
assessing the use of novel CDC7 inhibitors as treatments for solid cancers, but the preclinical
data has not been published regarding these compounds. DDK seems to be a promising target for
inhibition as cancer therapy, and it will be important to discover other novel and established
therapies that may work well in combination with DDK inhibitors.
Another important gene in DNA replication and DNA repair is RAD27, the yeast
orthologue of flap structure-specific endonuclease 1 (FEN1). The functions of the protein
products of these genes are to remove 5’ overhanging flaps on Okazaki fragments during DNA
replication and to process similar structures during base excision repair. A synthetic genetic
interaction between MEC1 and RAD27 has been previously observed in S. cerevisiae (256).
However, high-throughput screens performed using siRNA in human cancer cells failed to
uncover this synthetic interaction, either looking for sensitivity to FEN1 inhibitors (257) or
sensitivity to ATR inhibitors (186). Two germ line mutations in FEN1 cause an increased
frequency of lung and gastrointestinal cancers (258,259). Although classically thought of as a
tumor suppressor since FEN1 is involved in maintaining genomic integrity, FEN1 expression is
upregulated in a number of different cancer types (260-263). High levels of FEN1 were also

47
associated with poor breast cancer survival (264). This could be due to the high rate of DNA
replication in cancer cells that requires an overexpression of proteins involved in DNA
replication. Inhibitors of FEN1 have been developed as a cancer therapy and have been shown to
induce the DDR, but the inhibitors are in the early phases of preclinical testing (265-267).
Important genes for this chapter along with their human orthologs and simplified functions are
listed in Table 3.1.
3.2 Materials and Methods
3.2.1 Strains
All single deletion yeast strains used in this study are from the deletion set (144) (GE
Dharmacon). The wild type yeast strain BY4741 was used as a control for the single deletion
studies. In mec1∆ deletion strains, the MEC1 allele was replaced with a LEU2 marker that allows
for growth in media lacking leucine. The SML1 allele was replaced with an allele that allows for
resistance to nourseothricin (clonNAT). Genes of interest (e.g. CSE2) were replaced with the
KANMX4 allele that provides resistance to G418. All double mutant strains contain the indicated
gene mutations in the BY4741 background with the addition of the can1∆::MFA1pr-HIS3 lyp1
sml1∆ alleles. The only exception is that the sml1∆ strain is from the deletion set and contains
the sml1∆ allele in the BY4741 background. However, the sml1∆ strain containing the
can1∆::MFA1pr-HIS3 lyp1 alleles in the BY4741 background was also analyzed and there was
no difference in growth rate. A multicopy plasmid, pYGWRNH1, was graciously received from
Andrés Aguilera that contains the RNH1 gene under the control of the GAL1 promoter (268).
This plasmid was transformed into strains using the LiAc/ss carrier DNA/PEG method as
described (269).
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Yeast Gene
MEC1
TEL1
CSE2
SRB2
DST1
HTZ1
DBF4
RAD27

Human Ortholog
ATR
ATM
MED9
MED20
TCEA1
H2A.V, H2A.Z
DBF4/ASK
FEN1

Role
DDR Protein Kinase
DDR Protein Kinase
Mediator Subunit
Mediator Subunit
Transcriptional Regulation
Transcriptional Regulation
DNA Replication
DNA Replication

Table 3.1 List of important genes studied in Chapter 3. MEC1 and genes confirmed to
synthetically interact with MEC1 in yeast are listed along with their human orthologs. A
simplified version of the functions of these genes is also listed.
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3.2.2 Synthetic Genetic Arrays
The initial high-throughput synthetic genetic array (SGA) analysis was performed at
University of Toronto in collaboration with the Charles Boone and Grant Brown laboratories.
Details about the protocol are as described (201). Briefly, MATα mec1∆ sml1∆ and sml1∆ strains
were mated with strains from the MATa deletion set library. The more recent screen also
included MATa hypomorphs and conditional mutants. Heterozygous diploids were then selected
and sporulated. MATa haploids containing mec1∆ sml1∆ or sml1∆ and the gene mutation of
interest were then selected. Cells were germinated and colonies were imaged. Image analysis
software was then used to analyze the colony sizes, and if the colony size was smaller than a
multiplicative effect of both gene mutations, a negative genetic interaction was inferred.
3.2.3. Random Spore Analysis
Media preparation and random spore analysis were performed as described (270).
Briefly, mec1∆ sml1∆ and sml1∆ MATα strains were mated with single mutant deletion MATa
strains. Heterozygous diploids were then selected with YEPD + G418/clonNAT (YPD
supplemented with 120 mg/L adenine, 0.2 mg/L G418, 0.1 mg/L clonNAT) and sporulated for
five days at 22°C on solid enriched sporulation medium or liquid SPO++ medium (1.5% (w/v)
potassium acetate, 0.25% (w/v) yeast extract, 0.25% (w/v) glucose, supplemented with 40 mg/L
each of adenine, uracil, and tyrosine, 20 mg/L each of histidine, leucine, lysine, tryptophan,
methionine, and arginine, 100 mg/L phenylalanine, and 350 mg/L threonine). Spores were then
plated

on
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–his/arg/lys

+

canavanine/thialysine,

SD/MSG

–his/arg/lys

+

canavanine/thialysine/G418, SD/MSG –his/arg/lys + canavanine/thialysine/clonNAT, SD/MSG
–his/arg/lys

+

canavanine/thialysine/G418/clonNAT,

canavanine/thialysine/clonNAT,

and

SD/MSG

SD/MSG

–his/arg/lys/leu

–his/arg/lys/leu

+
+

50
canavanine/thialysine/G418/clonNAT that each select for a different genotype. Plates were then
scanned for images after three days at 30°C (or four days at 23°C in the case of dbf4 mutants).
Tetrad analysis was performed similarly except after sporulation, tetrads were dissected from 10
asci and germinated on solid YPD at 30°C. The plate was imaged and ImageJ was used to
determine colony size. The colonies were then transferred to media that select for the different
gene deletions to determine the genotype of the colonies.
3.2.4 Growth Rate
To assess growth rate, all growth was performed at 30°C (or 23°C in the case of the dbf4
mutant experiments). Frozen stocks of strains were streaked onto YPD solid media and incubated
for at least three days. Single colonies were then transferred to SD/MSG (complete) liquid media
and incubated for approximately 24 hours. Overnight cultures were then diluted to OD600 of 0.2
and OD600 was measured at the indicated time points by spectrophotometry (Pharmacia Biotech).
3.2.5 HU Sensitivity
HU sensitivity experiments were performed by streaking strains from frozen stocks onto
solid YPD media. Single colonies were transferred to liquid YPD media (or synthetic complete
media lacking uracil for the strains carrying the RNH1 plasmid) and grown overnight at 30°C (or
23°C in the case of the dbf4 mutant experiment). Overnight cultures were normalized to the
strain with the lowest OD600 and serially diluted (1:10, 1:100, 1:1000, and 1:10000). Five µl of
each dilution was spotted onto SD/MSG (complete), SD/MSG (complete) + HU, SD/MSG/2%
Galactose (complete), and SD/MSG/2% Galactose (complete) + HU plates. 100 mM HU was
used for single mutant experiments, and 1 mM HU was used for double mutant experiments. In
the cases of dbf4 and rad27 single mutants, cultures were spotted onto YPD and YPD + 100mM
HU. dbf4 and rad27 double mutants were spotted onto YPD and YPD + 1 mM HU. Plates were
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grown at 30°C (or 23°C in the case of the dbf4 mutant experiment) and scanned after sufficient
growth.
3.2.6 DNA Content
Flow cytometry was used to measure DNA content. Overnight cultures were brought to
an OD600 of 0.2 and grown at 30°C (or 23°C in the case of the dbf4 experiment) for two hours.
Cultures were arrested with 2.5 µM alpha factor for two hours at 30°C (or 23°C in the case of the
dbf4 experiment) then alpha factor was removed and cells were washed with sterile water.
Samples were taken at the indicated time points, cells were fixed, and DNA was stained with
SYBR green I as in chapter 2 methods. The BD Canto II flow cytometer at the Microscopy,
Imaging, and Cytometry Resources Core at Wayne State University School of Medicine was
used for analysis
3.2.7 Cell Culture
Our human NSCLC work was done in Dr. Stephen Patrick’s lab using the A549, H460,
and H1299 cell lines. All incubations were performed at 37°C in 5% CO2. A549 cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)/high glucose media supplemented
with 10% fetal bovine serum, 1% penicillin/streptomycin solution, 1X minimal essential medium
(MEM) non-essential amino acid solution, and 1X HEPES buffer. H460 and H1299 cells were
cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin solution.
3.2.8 siRNA, shRNA, and Drug Treatments
Transfection of a non-targeting control shRNA and shRNA against MED9, MED20,
DBF4, and FEN1 was performed as previously described (271) except that we used a midi prep
kit (Qiagen). For the siRNA knockdown experiments, 200,000 cells were seeded, incubated
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overnight, and transfected with 5 µM of a pooled set of four siRNA in complete media with
0.2% DharmaFECT reagent #4 (GE Dharmacon) for 24 hours. The transfection was repeated for
another 24 hours. Cells were then treated with the indicated amounts of ATR inhibitor, VE-822
(Selleck Chemicals) for four hours in serum-free media. After treatment, media was replaced
with complete media and incubated until colonies formed. Cells were then stained with crystal
violet (1% w/v crystal violet in 80% ethanol solution) and colonies with more than 50 cells were
counted. Percent colony survival was calculated based on untreated cells. Error bars were plotted
using standard error. Dual VE-822 and XL-413 (Tocris) treatment was done similarly except the
treatments were done in complete media for 24 hours. Synergy was assessed by treating A549,
H460, and H1299 cells with varying concentrations of ATRi, DDKi, or the two in combination at
varying concentrations but an identical ratio for 24 hours in complete media. Colonies were
counted and values were used to create combination index values and to calculate the doses
required to affect 90% of cells using the CompuSyn program (272).
3.2.9 Protein
Yeast western blotting analyses were performed as in aim 1. Human cells were washed
with 1X PBS, and pellets were stored at -80°C. Protein was extracted in lysis buffer (10 mM Tris
pH 8.0, 120 mM NaCl, 0.5% NP-40, 1 mM EDTA) containing protease inhibitors (0.5 M phenyl
methyl sulphonyl fluoride, 1 mg/ml Leupeptin, 1 mg/ml pepstatin A) for 30 minutes on ice.
Protein resolution and transfer were performed as in chapter 2 methods. Antibodies included
anti-MED9 (Abcam), anti-DBF4 (Bethyl), anti-FEN1 (Santa Cruz Biotechnology), anti-PARP1
(Proteintech), MCM2 (Bethyl), anti-Phospho-MCM2 (S53) (Bethyl), and anti-α-tubulin (SigmaAldrich). Secondary antibodies were the same as described in aim 1 except we also used IRDye
800-conjugated anti-mouse (Rockland).
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3.3 Results
3.3.1 Synthetic Interactions between MEC1 and Transcription Regulators in S. cerevisiae
In collaboration with Charles Boone and Grant Brown at University of Toronto, a MEC1
SGA screen was performed. The mec1∆ sml1∆ and sml1∆ deletion strains were screened with
the gene deletion strain library. The screen resulted in ~200 prospective genes that synthetically
interact with MEC1 but not SML1 (Table 3.2). A previous SGA screen involving MEC1 only
discovered 16 synthetic genetic interactions (78). Ten of these interactions were also discovered
using our screen but two of them were found to interact with SML1 so were discarded from the
analysis. As expected, Gene Ontology analysis showed that genes involved in different aspects
of DNA metabolism, including DNA repair, the DDR, and DNA recombination likely
synthetically interact with MEC1. Interestingly, 36 genes involved in transcription from the RNA
polymerase II promoter were found to likely synthetically interact with MEC1 (Table 3.2). An
interesting subset of the synthetic genetic array results includes genes that encode subunits of the
Mediator complex (Table 3.3). Approximately half of the Mediator subunits are essential for
viability (273). Since strains with mutations in essential genes were not included in this screen,
there was considerable enrichment for Mediator subunits discovered in the MEC1 screen.
Mediator subunits were a focus of the work, but transcriptional regulators HTZ1 and DST1 were
also studied. HTZ1 is a histone variant and DST1 is a general transcription elongation factor.
A subset of the genes that were identified in our screen was selected for further study.
Random spore analysis was performed to confirm the synthetic genetic interactions (see
Methods). Random spore analysis has confirmed the synthetic genetic interactions between
MEC1 and CSE2, SRB2, DST1, and HTZ1 (Figures 3.1, 3.2, 3.3, 3.4 and Table 3.2). HHO1 was
used as a negative control to ensure that the small colony size of the triple mutants was not due
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Yeast Gene Protein description

Random Spore Analysis Human Gene

Table 3.2 Gene Ontology analysis of genes that synthetically interact with MEC1. The P-value is
derived from a c2 test where the percentage of genes with a certain gene ontology annotation out
of the total number of genes revealed from the synthetic genetic array is compared with the
frequency of genes containing the same gene ontology annotation out of the entire genome.
Genes exhibiting possible synthetic interactions with leu2 were not excluded from this analysis.
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CSE2

Mediator subunit, middle module

yes

MED9

NUT1

Mediator subunit, middle module

yes

MED5

SRB2

Mediator subunit, middle module

yes

MED20

SRB8

Mediator subunit, Cdk8 module

yes

MED12

HTZ1

Histone variant H2AZ

yes

H2A.V, H2A.Z

DST1

General transcription factor TFIIS

yes

TCEA1

Table 3.3 Genes of interest confirmed to synthetically interact with MEC1 with the initial SGA
screen.
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Figure 3.1 Random spore analysis validates the interaction between MEC1 and CSE2 using
the cse2∆ allele. Top panel) A haploid MATa cse2∆ strain was mated with a mec1∆ sml1∆
MATα haploid strain. The heterozygous diploid strain was then sporulated and plated onto media
that selects for certain MATa mutants and left to germinate. Bottom panel) A haploid MATa
cse2∆ strain was mated with a sml1∆ MATα haploid strain, sporulated, and plated onto selection
media to ensure the synthetic interaction was not between CSE2 and SML1.
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Figure 3.2 Random spore analysis validates the interaction between MEC1 and SRB2 using
the srb2∆ allele. Top panel) A haploid MATa srb2∆ strain was mated with a mec1∆ sml1∆
MATα haploid strain. The heterozygous diploid strain was then sporulated and plated onto media
that selects for certain MATa mutants and left to germinate. Bottom panel) A haploid MATa
srb2∆ strain was mated with a sml1∆ MATα haploid strain, sporulated, and plated onto selection
media to ensure the synthetic interaction was not between SRB2 and SML1.
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Figure 3.3 Random spore analysis validates the interaction between MEC1 and DST1 using
the dst1∆ allele. Top panel) A haploid MATa strain containing the dst1∆ allele was mated with a
mec1∆ sml1∆ MATα haploid strain. The heterozygous diploid strain was then sporulated and
plated onto media that selects for certain MATa mutants and left to germinate. Bottom panel) A
haploid MATa dst1∆ strain was mated with a sml1∆ MATα haploid strain, sporulated, and plated
onto selection media to ensure the synthetic interaction was not between DST1 and SML1.
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Figure 3.4 Random spore analysis validates the interaction between MEC1 and HTZ1 using
the htz1∆ allele. Top panel) A haploid MATa strain containing the htz1∆ allele was mated with a
mec1∆ sml1∆ MATα haploid strain. The heterozygous diploid strain was then sporulated and
plated onto media that selects for certain MATa mutants and left to germinate. Bottom panel) A
haploid MATa htz1∆ strain was mated with a sml1∆ MATα haploid strain, sporulated, and plated
onto selection media to ensure the synthetic interaction was not between HTZ1 and SML1.
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to an artifact of the media. Indeed, the colony size of the hho1∆ mec1∆ sml1∆ strain is similar to
the size of wild type colonies (Figure 3.5). The random spore analysis method was also used to
confirm the synthetic interaction between TEL1 and MEC1 (Figure 3.6), which was previously
established (165) and identified in our screen. Another method to verify synthetic genetic
interactions is to perform tetrad dissections on diploids heterozygous for the two gene mutations.
Tetrad analysis with the heterozygous cse2∆ mec1∆ strain showed that cse2∆ mec1∆ haploids
form smaller colonies than single or double mutants, again verifying the synthetic sickness
phenotype (Figure 3.7).
A more quantitative approach to measuring the genetic interactions we are interested in is
performing growth rate analysis of the single, double, and triple mutant strains. In each case, the
double mutant strain (e.g. cse2∆ mec1∆) grew considerably slower than the wild type or single
mutant strains (Figures 3.8, 3.9, 3.10, 3.11). This quantitatively confirms the genetic interactions
between MEC1 and CSE2, SRB2, DST1, and HTZ1.
Clearly, there are genetic interactions between genes involved in transcription or DNA
replication and the DDR. Therefore, MEC1 may be offering some protection after Mediator
subunits or genes involved in DNA replication are deleted. We hypothesized that deletion of
transcription genes causes DNA damage that can only be repaired by a pathway involving
MEC1. A mutation in SRB2 causes sensitivity to long-term treatment with the alkylating agent
methyl methanesulfonate (274). Deletion of SRB2 also makes cells more sensitive to methyl
methanesulfonate (275), indicating that SRB2 defects may cause a defect in DNA repair. Perhaps
DNA damage builds up when certain Mediator subunits are mutant because of decreased
transcription of DNA repair genes. Deletion of the MED12 subunit of the Mediator complex
resulted in increased genomic instability (personal correspondence, Aleksandar Rajkovic), and if
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Figure 3.5 Random spore analysis was performed to verify that HHO1 and MEC1 do not
synthetically interact as a negative control. Top panel) A haploid MATa hho1∆ strain was
mated with a mec1∆ sml1∆ MATα haploid strain. The heterozygous diploid strain was then
sporulated and plated onto media that selects for certain MATa mutants and left to germinate.
Bottom panel) A haploid MATa hho1∆ strain was mated with a sml1∆ MATα haploid strain,
sporulated, and plated onto selection media.
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Figure 3.6 Random spore analysis confirms the TEL1 and MEC1 synthetic interaction as a
positive control. Top panel) A haploid MATa tel1∆ strain was mated with a mec1∆ sml1∆ MATα
haploid strain. The heterozygous diploid strain was then sporulated and plated onto media that
selects for certain MATa mutants and left to germinate. Bottom panel) A haploid MATa tel1∆
strain was mated with a sml1∆ MATα haploid strain, sporulated, and plated onto selection media
to ensure the synthetic interaction was not between TEL1 and SML1.
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Figure 3.7 Tetrad dissection of a heterozygous cse2∆ mec1∆ sml1∆ strain validates the
synthetic genetic interaction between CSE2 and MEC1. A haploid MATa cse2∆ strain was
mated with a mec1∆ sml1∆ MATα haploid strain. The heterozygous diploid strain was then
sporulated, and 10 asci were dissected and left to germinate on rich media. The plate was then
replica plated to media that selects for the cse2∆ mec1∆ sml1∆ genotype, and a red circle denotes
these cells.

64
3
2.5

WT

OD600

2

mec1∆
1.5

cse2∆
1

cse2∆mec1∆
0.5
0
0

100

200

300

400

500

Time (Min)

Figure 3.8 Growth rate of single and double mutants in the sml1∆ background verifies the
synthetic genetic interaction between CSE2 and MEC1. Cells were brought to 0.2 OD600 in
SD/MSG (complete) media and grown at 30°C. OD600 was measured via spectrometry at regular
intervals to determine approximate cell density. Three independent experiments were performed,
and a representative experiment is shown.
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Figure 3.9 Growth rate of single and double mutants in the sml1∆ background verifies the
synthetic genetic interaction between SRB2 and MEC1. Cells were brought to 0.2 OD600 in
SD/MSG (complete) media and grown at 30°C. OD600 was measured via spectrometry at regular
intervals to determine approximate cell density. Three independent experiments were performed,
and a representative experiment is shown.
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Figure 3.10 Growth rate of single and double mutants in the sml1∆ background verifies the
synthetic genetic interaction between DST1 and MEC1. Cells were brought to 0.2 OD600 in
SD/MSG (complete) media and grown at 30°C. OD600 was measured via spectrometry at regular
intervals to determine approximate cell density. Three independent experiments were performed,
and a representative experiment is shown.
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Figure 3.11 Growth rate of single and double mutants in the sml1∆ background verifies the
synthetic genetic interaction between HTZ1 and MEC1. Cells were brought to 0.2 OD600 in
SD/MSG (complete) media and grown at 30°C. OD600 was measured via spectrometry at regular
intervals to determine approximate cell density. Three independent experiments were performed,
and a representative experiment is shown.
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other Mediator subunits behave similarly, would lend credence to this hypothesis. Based on the
genetic interactions between transcription genes and MEC1 and the hypothesis that loss of
transcription genes leads to DNA damage, Mec1 should be activated in strains lacking
transcriptional regulation genes. Mec1 catalyzes phosphorylation of a number of substrates in
order to initiate the DDR, so examining phosphorylation of these protein substrates can give us
an idea of whether or not Mec1 has been activated. Mec1 catalyzes phosphorylation of H2A
early in the DDR to generate λ-H2A, which is also widely used as a marker for DNA DSBs
(79,80). Contrary to our hypothesis, λ-H2A levels were undetectable in Mediator subunit
deletion strains (Figure 3.12). λ-H2A is usually only correlated with DNA DSBs, while Rad53 is
phosphorylated in response to many types of DNA damage. So, unless large increases of DNA
DSBs are initiated in response to loss of transcription genes, then Rad53 may be a better
indicator of Mec1 activation. Mec1 phosphorylates Rad53, which then leads to
autophosphorylation and activation of Rad53 (81). An antibody that recognizes both the
phosphorylated and unphosphorylated forms of Rad53 was used to examine Mec1 pathway
activity. Unexpectedly, Rad53 expression was approximately equal between wild type and
Mediator subunit deletion strains, and Rad53 phosphorylation was undetectable (Figure 3.13).
This indicates that the Mec1 DDR pathway is not activated in strains lacking certain Mediator
subunits. However, the western blotting methods to detect λ-H2A and Rad53 phosphorylation
may not be sensitive enough to detect small differences in DNA damage. We hypothesized that
Mediator subunit deletion is causing replication stress or conflicts between transcription and
replication machineries that requires Mec1 to resolve. This could be the reason for the higher
mutation frequency observed in the srb2∆ strain (276). Based on this hypothesis, Mediator
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Figure 3.12 λ-H2A expression in synchronized wild type and single mutant strains.
Overnight cultures were brought to 0.2 OD600 and grown at 30° C for two hours in YPD. Cells
were synchronized in G1 phase by incubating cells with 2.5 µM alpha factor in YPD for two
hours at 30°C. Alpha factor was removed and cells were placed back into YPD and samples were
taken at indicated time points. 0 and 24-hour YGB604 (SIC1∆PHA dmc1∆) samples from a
synchronous sporulation experiment were used as a positive control for λ-H2A expression.
Protein was isolated from these samples and λ-H2A and tubulin expression was visualized via
western blot.
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Figure 3.13 Rad53 expression in synchronized wild type and single mutant strains.
Overnight cultures were brought to 0.2 OD600 and grown at 30°C for two hours in YPD. Cells
were synchronized in G1 phase by incubation with 2.5 µM alpha factor in YPD for two hours at
30°C. Alpha factor was removed and cells were placed back into YPD and samples were taken at
indicated time points. Strains treated with 100mM HU for 0 and 90 minutes were used as
controls. YGB138 (WT) and YGB814 (rad53∆) were used as positive and negative controls,
respectively. Western blot was then used to visualize Rad53 and tubulin expression.
*a non-specific band.
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subunit deletion strains would show increased sensitivity to a compound that induces replication
stress.
HU inhibits ribonucleotide reductase, the enzyme that catalyzes the rate-limiting step in
the synthesis of deoxyribonucleotides. This inhibition reduces the deoxynucleoside triphosphate
pools, which are necessary for proper DNA synthesis during S phase (277). Therefore, a
heightened sensitivity to HU indicates a defect in S phase when DNA is replicating. A previous
study found a synthetic genetic interaction between MEC1 and HPR1, which is involved in
mRNA metabolism and export. Double mutant strains showed a hypersensitivity to HU
compared with either single mutant, which indicates an S-phase specific effect in the double
mutant. The hpr1∆ strain was ultimately found to show an increase in R-loop formation (268).
Experiments were performed to examine HU sensitivity of single and double mutants of MEC1
and genes involved in transcription. First, any strain containing mec1∆ sml1∆ was extremely
sensitive to HU, which was established previously (39,113). The htz1∆ and srb2∆ single mutant
strains showed a higher sensitivity to HU than the matched wild type strain (Plates on left side of
Figure 3.14 and Figure 3.15). Deletion of HTZ1 has previously been observed to lower resistance
to HU (278-280). Deletion of SRB2 has been shown to decrease resistance to HU
(278,279,281,282). However, one study showed that resistance to HU was increased by deletion
of SRB2 (283). This indicates that the loss of genes involved in transcription can cause S phase
specific events that cause a hypersensitivity to HU. Double mutants (e.g. cse2∆ mec1∆) were
also examined for HU hypersensitivity. However, since strains with mec1 mutations are
exquisitely sensitive to HU, a lower concentration of HU had to be used to study these strains.
The cse2∆ mec1∆ and srb2∆ mec1∆ strains were more sensitive to 1 mM HU than mec1∆ cells
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Figure 3.14 The srb2∆ strain carrying the RNAse H plasmid is less sensitive to HU on
galactose-containing media. WT and single mutant strains were carrying a plasmid where
RNAse H is under the control of the GAL1 promoter. Overnight cultures were serially diluted
(1:10, 1:100, 1:1000, and 1:10000) and 5 µl of each dilution was spotted onto SD/MSG
(complete), SD/MSG (complete) + 100mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal
(complete) + 100mM HU plates. Plates were incubated at 30°C for two days and scanned.

73

Figure 3.15 The htz1∆ strain carrying the RNAse H plasmid is less sensitive to HU on
galactose-containing media. WT and single mutant strains were carrying a plasmid where
RNAse H is under the control of the GAL1 promoter. Overnight cultures were serially diluted
(1:10, 1:100, 1:1000, and 1:10000) and 5 µl of each dilution was spotted onto SD/MSG
(complete), SD/MSG (complete) + 100mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal
(complete) + 100mM HU plates. Plates were incubated at 30°C for two days and scanned.
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(Figures 3.16, 3.17). This further lends credence to our hypothesis that deletion of Mediator
subunits causes DNA damage or replication stress. However, it is also possible that the
transcriptional response to HU is compromised.
Since a clear S-phase event is happening in several of the single mutant strains, the
mechanism causing this HU hypersensitivity was examined. Since the hpr1∆ strain was found to
harbor an increased level of R-loops, we attempted to examine the effect of R-loops in the single
and double mutant strains. Yeast strains were transformed with a plasmid that contains the
RNase H1 (RNH1) gene under the control of the GAL1 promoter. In the presence of galactose,
strains carrying this plasmid overexpress RNAse H, which degrades RNA:DNA hybrids to
reduce R-loop levels (63). It has been hypothesized that reduction of sensitivity to HU by RNase
H indicates R-loop formation (268). Indeed, single and double mutant strains carrying the
RNAse H plasmid that are normally sensitive to HU were more resistant to HU in the presence
of galactose. The srb2∆ and htz1∆ single mutant strains displayed this phenotype (Figures 3.14,
3.15). The srb2∆ mec1∆ strain carrying the RNAse H plasmid also showed a higher resistance to
1 mM HU in the presence of galactose (Figure 3.17). Interestingly, the cse2∆ mec1∆ strain
carrying the plasmid showed the opposite effect, a heightened sensitivity to HU when grown on
media containing galactose (Figure 3.16). This indicates that RNAse H expression was rescuing
the HU sensitivity of certain strains. However, it was found that the srb2∆ strain without the
RNAse H plasmid also showed heightened resistance to HU in the presence of galactose (Figure
3.18). Therefore, the presence of galactose in the media was rescuing the strains’ sensitivities to
HU. We hypothesize that the transcriptional response to galactose was benefitting certain
Mediator subunit deletion strains in the response to replication stress induced by HU. Since the
rescue of sensitivity to HU was at least in part mediated by the presence of galactose in the srb2∆
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Figure 3.16 The cse2∆ mec1∆ strain carrying the RNAse H plasmid is more sensitive to HU
on galactose-containing media. HU sensitivity of wild type, single, and double mutant strains
was assessed. All strains contain the sml1∆ background and were carrying a plasmid where
RNAse H is under the control of the GAL1 promoter. Overnight cultures were serially diluted
(1:10, 1:100, 1:1000, and 1:10000) and 5 µl of each dilution was spotted onto SD/MSG
(complete), SD/MSG (complete) + 1mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal
(complete) + 1mM HU plates. Plates were incubated at 30°C for two days and scanned.
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Figure 3.17 The srb2∆ mec1∆ strain carrying the RNAse H plasmid is more resistant to HU
on galactose-containing media. HU sensitivity of wild type, single, and double mutant strains
was assessed. All strains contain the sml1∆ background and were carrying a plasmid where
RNAse H is under the control of the GAL1 promoter. Overnight cultures were serially diluted
(1:10, 1:100, 1:1000, and 1:10000) and 5 µl of each dilution was spotted onto SD/MSG
(complete), SD/MSG (complete) + 1mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal
(complete) + 1mM HU plates. Plates were incubated at 30°C for two days and scanned.
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Figure 3.18 The srb2∆ strain is less sensitive to HU on galactose-containing media. These
strains were carrying no plasmid. Overnight cultures were serially diluted (1:10, 1:100, 1:1000,
and 1:10000) and 5 µl of each dilution was spotted onto SD/MSG (complete), SD/MSG
(complete) + 100mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal (complete) + 100mM HU
plates. Plates were grown at 30°C for two days and scanned.
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strain, it was impossible to analyze whether overexpression of RNAse H had any effect on
sensitivity to HU. However, it is clear that deletion of certain genes involved in transcriptional
regulation results in sensitivity to HU.
Deletion of a Mediator subunit may cause replication stress, which then activates the
Mec1 checkpoint and eventually results in cell cycle arrest. In order to investigate cell cycle
progression, DNA content was analyzed in these strains at different time points of cell cycle
progression via flow cytometry. Examining the cell cycle profile of yeast strains containing
deletions of Mediator subunits that genetically interact with MEC1 can provide clues as to
whether the cell cycle is being arrested. Flow cytometry is used to determine the DNA content in
individual cells, which indicates which phase of the cell cycle the cell was in when it was
collected, G1, S, or G2/M phase. Comparing the percentage of cells at each phase of the cell
cycle between wild type and mutants can be informative as to whether the cells are arresting at a
certain stage of the cell cycle and can infer if the DDR checkpoint is being activated. First, the
strains are grown to exponential phase and arrested in G1 phase with yeast mating alpha factor.
The strains are then released from alpha factor and flow cytometry samples are taken at various
time points. A cell cycle analysis experiment was performed using a wild type strain and two
strains containing deletions of Mediator subunits, cse2∆ and srb2∆. In the cse2∆ strain, there
appears to be a greater percentage of cells in G1 phase at the 20 and 40-minute time points
(Figure 3.19). This may indicate that the G1/S or intra-S checkpoint is activated. The srb2∆
strain appears to be delayed during the G1/S transition, and these cells do not catch up to wild
type cells during the 120-minute time course (Figure 3.19). One or more checkpoints may be
activated in this mutant strain. Cell cycle analysis was also performed on double and triple
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Figure 3.19 Synchronized cell cycle profiles of wild type and single mutant cse2∆ and srb2∆
strains. Cells were grown overnight in SD/MSG (complete) media then diluted to OD600 of 0.2
and grown for two hours at 30°C. They were synchronized with alpha factor for two hours in
SD/MSG (complete) at 30°C. Alpha factor was removed and cultures were grown at 30°C in
YPD. Samples were taken every 20 minutes for two hours, fixed, and prepared for flow
cytometry analysis.
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mutant strains, such as the srb2∆ mec1∆ sml1∆ strain, but there was no difference in cell cycle
dynamics between this strain and the srb2∆ or srb2∆ sml1∆ strains (Figure 3.20).
3.3.2 Synthetic Interactions Between MEC1 and DBF4 or RAD27 in S. cerevisiae
The SGA was performed again in collaboration with Drs. Boone and Brown, this time
including strains containing conditional mutants and hypomorphs of essential genes. Several
interesting genes involved in DNA replication and repair, DBF4 and RAD27, were found to
synthetically interact with MEC1. We discovered these interactions by analyzing the data from
the SGA screen. “Jackknife” genetic interactions were first removed, where colony size differed
significantly from its technical replicates (284). The mean and standard deviation of the
remaining interaction scores were then calculated. The scores outside of the mean plus or minus
the standard deviation multiplied by two were deemed to be robust interactions. Using this cutoff
in only the deletion strains, the TEL1 and DST1 interactions were confirmed. Strangely, the
interaction between MEC1 and the other transcription regulators were not observed with the new
SGA screen, though the interactions were verified via random spore analysis. When using this
cutoff, the rad27∆ strain likely formed a synthetic genetic interaction with the mec1∆ sml1∆
strain but not the sml1∆ strain. Also, analysis of the SGA results revealed two conditional dbf4
mutants likely to synthetically interact with MEC1 but not SML1, dbf4-2 and dbf4-ts. Another
allele, dbf4-1, fell just outside of the cutoff used for the analysis but was within one standard
deviation from the mean interaction score. Two mutant cdc7 alleles fell within one standard
deviation from the mean as well, suggesting an interaction between MEC1 and the genes
encoding DDK. Interestingly, random spore analysis was only able to verify one of the DBF4
interactions, a mutant containing the dbf4-1 allele (Figure 3.21). This allele has been reported to
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Figure 3.20 Synchronized cell cycle profiles of srb2∆, srb2∆ sml1∆, and srb2∆ mec1∆ sml1∆
strains. Cells were grown overnight in SD/MSG (complete) media then diluted to OD600 of 0.2
and grown for two hours at 30°C. They were synchronized with alpha factor for two hours in
SD/MSG (complete) at 30°C. Alpha factor was removed and cultures were grown at 30°C in
YPD. Samples were taken every 20 minutes for two hours, fixed, and prepared for flow
cytometry analysis.
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Figure 3.21 Random spore analysis validates the interaction between MEC1 and DBF4
using the dbf4-1 allele. Top panel) A haploid MATa strain containing the dbf4-1 allele was
mated with a mec1∆ sml1∆ MATα haploid strain. The heterozygous diploid strain was then
sporulated and plated onto media that selects for certain MATa mutants and left to germinate.
Bottom panel) A haploid MATa dbf4-1 strain was mated with a sml1∆ MATα haploid strain,
sporulated, and plated onto selection media to ensure the synthetic interaction was not between
DBF4 and SML1.
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be a P277L mutation (90), which was verified by sequencing. This mutation is predicted to not
be tolerated by SIFT mutation algorithm (285) and probably damaging by Polyphen 2 mutation
algorithm (286). Random spore analysis was also used to verify the synthetic interaction between
MEC1 and RAD27 using the rad27∆ allele. This was a very robust interaction, as can be
visualized by the extremely small colony size of the rad27∆ mec1∆ strain compared with single
mutant strains (Figure 3.22).
Growth rate analysis was performed to quantify the effect of the synthetic genetic
interactions between MEC1 and DBF4 or RAD27. The dbf4-1 mec1∆ and rad27∆ mec1∆ strains
grow slowly compared to the single mutants (Figures 3.23, 3.24). This lends quantitative
evidence to the synthetic interactions between MEC1 and DBF4 or RAD27. The DBF4 and
RAD27 genes were then cloned into pRS306 integrating plasmids so that after transformation of
these plasmids into triple mutant strains, the wild type gene would integrate into the endogenous
locus. We hypothesized that gene add-back would rescue the impaired growth phenotype of the
triple mutant strains. Indeed, adding the wild type DBF4 gene into the dbf4-1 mec1∆ strain
rescued the growth rate back to mec1∆ levels (Figure 3.23). Interestingly, add-back of wild type
RAD27 into the rad27∆ mec1∆ strain only partially rescued the growth phenotype (Figure 3.24).
This suggests that the impaired growth phenotype of the rad27∆ mec1∆ strain is partly due to
other mutations distinct from the RAD27 deletion (see Discussion).
We hypothesized that mutations in genes involved in DNA replication and repair would
cause defects during S phase. Mutations in DBF4 could cause aberrant DNA replication
initiation, and reduced nucleotide pools from HU treatment could exacerbate this problem.
Deletion of RAD27 causes defects in Okazaki fragment processing, and again, reduction in
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Figure 3.22 Random spore analysis validates the interaction between MEC1 and RAD27
using the rad27∆ allele. Top panel) A haploid MATa rad27∆ strain was mated with a mec1∆
sml1∆ MATα haploid strain. The heterozygous diploid strain was then sporulated and plated onto
media that selects for certain MATa mutants and left to germinate. Bottom panel) A haploid
MATa rad27∆ strain was mated with a sml1∆ MATα haploid strain, sporulated, and plated onto
selection media to ensure the synthetic interaction was not between RAD27 and SML1.
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Figure 3.23 Growth rate of single and double mutants in the sml1∆ background verifies the
synthetic genetic interaction between DBF4 and MEC1. Cells were brought to 0.2 OD600 in
SD/MSG (complete) media and grown at 23°C. OD600 was measured via spectrometry at regular
intervals to determine approximate cell density. Three independent experiments were performed,
and a representative experiment is shown.
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Figure 3.24 Growth rate of single and double mutants in the sml1∆ background verifies the
synthetic genetic interaction between RAD27 and MEC1. Cells were brought to 0.2 OD600 in
SD/MSG (complete) media and grown at 30°C. OD600 was measured via spectrometry at regular
intervals to determine approximate cell density. Three independent experiments were performed,
and a representative experiment is shown.
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nucleotide pools would probably aggravate this defect. Therefore, we hypothesized that
mutations in DBF4 or deletion of RAD27 would cause a hypersensitivity to HU in wild type and
mec1∆ backgrounds. Interestingly, wild type levels of sensitivity to HU were found in the
rad27∆ strain and dbf4 mutant strains (Figure 3.25). It was then hypothesized that Mec1 may
provide a protective effect in response to HU when DBF4 or RAD27 was mutated. However,
there was no change in sensitivity to HU in the rad27∆ mec1∆ or dbf4-1 mec1∆ strains compared
to the mec1∆ strain (Figures 3.26, 3.27).
We hypothesized that mutations in genes critical for DNA replication would cause
defects in cell cycle progression. A cell cycle analysis in WT and dbf4 mutant strains was
performed at a permissive temperature. A previous study showed that a dbf4 mutant strain arrests
in S phase when grown at the restrictive temperature of 37°C (287). Our experiment shows a cell
cycle delay in G1 and early S phase in multiple dbf4 mutant strains including the dbf4-1 strain
(Figure 3.28).
3.3.3 Synthetic Interactions are Recapitulated in Human Cancer Cells
It was next investigated whether synthetic interactions between MEC1 and genes
involved in transcription regulation or DNA replication were conserved in human cancer cells.
The tumor suppressor protein p53 could also be investigated as to whether it was involved in the
interactions. This type of analysis can only be conducted using human cells, since there is no
known ortholog of TP53 in S. cerevisiae (288). Non-small cell lung cancer (NSCLC) cell lines
were chosen primarily because cisplatin is often used in the treatment of NSCLC, and ATR
inhibitors have been found to potentiate the effects of cisplatin in vitro and in vivo (289-293).
Importantly, TP53 mutations are present in approximately half of all NSCLC patients (294-298).
FEN1 is also often over expressed in NSCLC (263) and ATM is mutated in approximately 7% of
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Figure 3.25 dbf4 mutations or rad27∆ do not change HU resistance. HU sensitivity was
assessed in wild type and single mutant strains. Overnight cultures were serially diluted (1:10,
1:100, 1:1000, and 1:10000) and 5 µl of each dilution was spotted onto SD/MSG (complete),
SD/MSG (complete) + 100mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal (complete) +
100mM HU plates. Plates were grown at 30°C for two days and scanned.
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Figure 3.26 rad27∆ does not affect HU resistance in the mec1∆ background. HU sensitivity
was assessed in wild type, single, and double mutant strains. All strains contain the sml1∆
background. Overnight cultures were serially diluted (1:10, 1:100, 1:1000, and 1:10000) and 5 µl
of each dilution was spotted onto SD/MSG (complete), SD/MSG (complete) + 1mM HU,
SD/MSG/Gal (complete), and SD/MSG/Gal (complete) + 1mM HU plates. Plates were grown at
30°C for two days and scanned.
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Figure 3.27 The dbf4-1 mutation does not affect HU resistance in the mec1∆ background.
HU sensitivity was assessed in wild type, single, and double mutant strains. All strains contain
the sml1∆ background. Overnight cultures were serially diluted (1:10, 1:100, 1:1000, and
1:10000) and 5 µl of each dilution was spotted onto SD/MSG (complete), SD/MSG (complete) +
1mM HU, SD/MSG/Gal (complete), and SD/MSG/Gal (complete) + 1mM HU plates. Plates
were grown at 30°C for two days and scanned.
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Figure 3.28 Synchronized cell cycle profiles of wild type, and single mutant dbf4 strains.
Cells were grown overnight in rich media (YPD) then diluted to OD600 of 0.2 and grown for two
hours at 23°C in YPD. They were synchronized with alpha factor for two hours in YPD at 23°C.
Alpha factor was removed and cultures were grown at 23°C in YPD. Samples were taken every
30 minutes for two hours, fixed, and prepared for flow cytometry analysis.
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lung adenocarcinomas (299). Since these genes form synthetic interactions with ATR, this could
mean that ATR inhibitors are more effective in NSCLC cells. The work was done primarily in
three NSCLC cell lines, large cell lung carcinoma NCI-H460, non-small cell lung carcinoma
NCI-H1299, and lung adenocarcinoma A549. The H460 and A549 cell lines contain wild type
p53 while the H1299 cell line is null for p53 expression (300). Preliminary data indicated that
shRNA knockdown of FEN1, DBF4, MED9, and to a lesser extent MED20 (the human orthologs
of the Mediator subunits and DNA replication genes that were found to synthetically interact
with MEC1) sensitized H460 cells to a small-molecule inhibitor of ATR, VE-822 (Figure 3.29).
This suggested that orthologs of yeast genes that interact with MEC1 interact with ATR in a
human NSCLC cell line. However, there was poor knockdown of the gene targets possibly
because of toxicity associated with loss of these gene products. Deletion of FEN1 (301) or CDC7
(302) has been shown to cause early embryonic lethality in mice, and many subunits of the
Mediator complex are also essential for embryonic development in mice (303-306). We
hypothesized that long-term knockdown of these genes is toxic, so the cells that had efficient
knockdown died and only cells with less efficient knockdown remained.
To overcome this effect, we opted for knockdown using transient siRNA that were
posited to be less toxic. A pooled set of four different siRNA (GE Dharmacon) were used to
knockdown expression of one of four genes, MED9 (hCSE2), MED20 (hSRB2), FEN1
(hRAD27), and DBF4 along with a non-targeting scrambled pool of siRNAs as a control in two
human NSCLC cell lines. The levels of mRNA of the targeted genes were quantified and
normalized to the housekeeping gene, GAPDH. In H460 cells there was 96% reduction of levels
of MED20, 93% reduction of levels of DBF4, and 87% reduction of levels of FEN1. In H1299
cells, levels of MED20 were reduced by 85%, DBF4 by 72%, and FEN1 by 77%. Western
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Figure 3.29 Knockdown of MED9, MED20, DBF4, or FEN1 sensitizes H460 cells to ATRi.
H460 cells treated with shRNA were treated for four hours with indicated doses of VE-822
(ATRi) in serum-free media. Media was replaced with complete media and cells were left to
grow until colonies formed with more than 50 cells. Cells were then stained with crystal violet
and colonies with more than 50 cells were counted. Cells treated with shRNA against the four
genes were compared with cells treated with scrambled shRNA. This data is based on a single
experiment with three replicates. Error bars are based on standard deviation between the three
replicates.
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blotting was also performed on MED9, DBF4, and FEN1 in H1299 cells and found reduced
protein levels of each after knockdown with their respective siRNA (Figure 3.30). The
knockdown cells were treated with an ATR inhibitor (ATRi), VE-822. This time, there was no
sensitization of the knockdown cells to ATRi in the H460 cell line (Figure 3.31). The identical
experiment was performed using the H1299 cell line and the original results from the H460
shRNA knockdown experiments were recapitulated. After knockdown of MED9, MED20, FEN1,
or DBF4, H1299 cells were sensitized to the ATRi (Figure 3.30).
3.3.4 Synergistic Effects of ATR and DDK Inhibitors in p53 Null Cells
We hypothesized that chemical inhibition of MED9, MED20, DBF4, or FEN1 using
small-molecule inhibitors would show the same effect as genetic knockdown. An inhibitor exists
of CDC7 (the catalytic subunit of DDK), XL-413 (DDKi). As noted before, this drug appears to
be highly specific for DDK (253). We found that phosphorylation of MCM2 at serine 53, a target
of DDK, was decreased after treatment with DDKi (Figure 3.32). This indicates that DDKi was
inhibiting the catalytic activity of DDK. H1299 cells were treated with escalating doses of DDKi
with or without a dose of ATRi that prevented approximately 50% of colony formation as a
single treatment. ATRi treatment sensitized H1299 cells to DDK inhibition by ~10-fold (Figure
3.33). Based on these data, small-molecule inhibitors of ATR and DBF4 may be synergistic in
the H1299 cell line. H1299, A549, or H460 cells were treated with single drugs and different
doses but an identical ratio of the two drugs using a standard colony assay. CompuSyn (272) was
then used to analyze the data and create combination index values. The dose of each single drug
required to prevent 90% of colony formation was plotted on the axes and a line was drawn
between them. The combination index values were then used to calculate the dose of the DDKi
required to prevent 90% of colony formation in combination with the indicated dose of ATRi. If
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Figure 3.30 Knockdown of MED9, MED20, DBF4, or FEN1 with siRNA sensitizes H1299
cells to ATRi. H1299 cells treated with siRNA were treated for four hours with indicated doses
of VE-822 (ATRi) in serum-free media. Media was replaced with complete media and cells were
left to grow until colonies formed with more than 50 cells. Cells were then stained with crystal
violet and colonies with more than 50 cells were counted. Cells treated with siRNA against the
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four genes were compared with cells treated with non-targeting siRNA. The data is the average
of three independent experiments each with three replicates. Error bars are calculated based on
standard error between the three experiments. Samples for protein analysis were collected on the
same day cells were seeded, which was the day before treatment. Western blotting validated that
siRNA against MED9, DBF4, or FEN1 decreased protein levels.
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Figure 3.31 Knockdown of MED9, MED20, DBF4, or FEN1 with siRNA does not sensitize
H460 cells to ATRi. H460 cells treated with siRNA were treated for four hours with indicated
doses of VE-822 (ATRi) in serum-free media. Media was replaced with complete media and
cells were left to grow until colonies formed with more than 50 cells. Cells were then stained
with crystal violet and colonies with more than 50 cells were counted. Cells treated with siRNA
against the four genes were compared with cells treated with non-targeting siRNA. This data is
based on a single experiment with three replicates. Error bars are based on standard deviation
between the three replicates.
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Figure 3.32 Phospho-MCM2 is decreased after treatment with DDKi. H460 (wild type and
p53 knockout) cells were treated for 24 hours with 125 nM VE-822 (ATRi) or 35 µM XL-413
(DDKi) as single drugs and in combination. Protein was harvested 24 hours after treatment and
western blotting was used to examine total MCM2, phospho-MCM2, and tubulin.
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Figure 3.33 Treatment with ATRi sensitizes H1299 cells to DDKi. H1299 cells were treated
for 24 hours with indicated doses of XL-413 (DDKi) with or without 150 nM VE-822 (ATRi), in
complete media. Media was replaced and cells were left to grow until colonies formed with more
than 50 cells. Cells were then stained with crystal violet and colonies with more than 50 cells
were counted. This data is based on a single experiment with three replicates. Error bars are
based on standard deviation between the three replicates.
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this value is above the line, the two drugs are antagonistic. If this value is along the line, the
drugs display an additive effect. If this value is below the line, the two drugs are synergistic.
Using this analysis, the ATRi and DDKi were found to be highly synergistic in the H1299 cell
line. Interestingly, the two drugs showed an additive or slightly antagonistic relationship in the
H460 and A549 cell lines (Figure 3.34).
Since H1299 cells do not express p53 and H460 and A549 cells express wild type p53,
we hypothesized that p53 has an effect on the functional interaction between ATR and DBF4. If
this were true, A549 or H460 cells where p53 is eliminated would be sensitized to ATR
inhibition by a DDK inhibitor. Exon 6 of TP53 was disrupted using the CRISPR/cas9 system in
the H460 and A549 cell lines that normally contain wild type TP53 to create p53 knockout
models (H460 p53∆ and A549 p53∆). Synergy analysis was performed using these cell lines, and
ATRi and DDKi were highly synergistic in the A549 p53∆ and H460 p53∆ cells (Figure 3.34).
This strongly suggests that synergy between ATRi and DDKi is dependent on the absence of
p53. CompuSyn was also used to calculate the combination index (CI) values obtained at
different doses of ATRi and DDKi. A CI value greater than one indicates antagonism, less than
one indicates synergy, and approximately one indicates an additive effect. We plotted the CI
value as a function of the doses of the two drugs. There is a trend towards more robust synergy at
the higher doses in the H1299 and H460 p53∆ cells. There is a slight trend towards lower
synergy in the A549 p53∆ cells at higher doses (Figure 3.35).
Interestingly, data from the synergy experiments showed that p53∆ cells were more
resistant to ATRi than their matched isogenic wild type counterparts in both A549 and H460 cell
lines (Figure 3.36). This is in disagreement with most findings thus far (see Discussion). A549
p53∆ cells were also observed to be more resistant to DDKi than A549 wild type cells. H460
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Figure 3.34 ATRi and DDKi synergize in cells without expression of p53. H1299, H460 (wild
type and p53 knockout) and A549 (wild type and p53 knockout) cells were treated for 24 hours
with varying doses of VE-822 (ATRi), XL-413 (DDKi) or ATRi and DDKi at a constant ratio in
complete media. Media was replaced and cells were left to grow until colonies formed with more
than 50 cells. Cells were then stained with crystal violet and colonies with more than 50 cells
were counted. The percentage of cells surviving treatment was calculated compared to vehicle
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treated control and converted to fraction affected. CompuSyn was used for data analysis. The
data is the average of three independent experiments each with three replicates. The dose
required for prevention of 90% of colony formation for ATRi is plotted on the x-axis and the
same value for DDKi is plotted on the y-axis. A line is then drawn between the points. The dose
of DDKi required to prevent 90% colony formation along with the indicated dose of ATRi was
calculated. If these points are below the line, there is a synergistic effect. If these points are along
the line, there is an additive effect between the drugs. If the points are above the line, the drugs
are antagonistic. Error bars are calculated based on standard error between three experiments.
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Figure 3.35 Synergy patterns differ with different doses in different cell lines. The
percentage of cells surviving treatment was calculated compared to vehicle treated control and
converted to fraction affected. CompuSyn was used to calculate combination index (CI) values
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using the data from Figure 3.34. A CI value over one, approximately one, or less than one
indicates that the two drugs are antagonistic, additive, or synergistic respectively.
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Figure 3.36 p53 knockout cells are more resistant to ATRi. H460 (wild type and p53
knockout) and A549 (wild type and p53 knockout) cells were treated for 24 hours with varying
doses of VE-822 (ATRi) in complete media. Media was replaced and cells were left to grow
until colonies formed with more than 50 cells. Cells were then stained with crystal violet and
colonies with more than 50 cells were counted. The data is the average of three independent
experiments each with three replicates. Error bars are calculated based on standard error between
the three experiments.
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p53∆ were only marginally more resistant to DDKi at the highest dose, but there was no
difference at the lower doses (Figure 3.37). In both cell lines, p53∆ cells displayed similar
sensitivities to the ATRi plus DDKi dual treatment (Figure 3.38). This indicates that synergy was
achieved in p53∆ cells because DDKi treatment overcame the resistance to ATRi. In A549 p53∆
cells it could also be that ATRi treatment overcame the resistance to DDKi (see Discussion).
We hypothesized that combination treatment of ATRi and DDKi was inducing p53independent apoptosis in NSCLC cell lines. In order to investigate, H460 WT and H460 p53∆
were treated with ATRi and DDKi alone or in combination. The cells were treated with doses of
ATRi and DDKi that prevent approximately 50% of colony formation. 24 hours after treatment,
protein was harvested and probed with a PARP1 antibody. Cleaved PARP1 is an established
marker for apoptosis (307-309). We found a greater amount of cleaved PARP1 in cells treated
with the combination treatment than in single drug treated cells or vehicle treated cells in both
WT and p53∆ H460 cells (Figure 3.39). This indicates that apoptosis is a significant mechanism
induced by ATRi and DDKi dual treatment in H460 cells even in cells lacking p53 expression.
3.4 Discussion
We discovered that adding back the wild type RAD27 into the rad27∆ mec1∆ mutant
strain did not completely rescue the observed growth defect (see Figure 3.24). It was perplexing
as to why the gene add-back did not completely rescue the impaired growth phenotype like the
wild type DBF4 gene rescued growth of the dbf4-1 mec1∆ strain. It is also interesting that
RAD27 shows synthetic genetic interactions with a multitude of different genes. When applying
a stringent cutoff to data from a SGA screen performed by the Boone lab, there were 330
negative genetic interactions with a rad27∆ allele (204). Perhaps there are secondary mutations
in the rad27∆ strain that are the culprit behind some of these synthetic genetic interactions. Since
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Figure 3.37 A549 p53 knockout cells are more resistant to DDKi. H460 (wild type and p53
knockout) and A549 (wild type and p53 knockout) cells were treated for 24 hours with varying
doses of XL-413 (DDKi) in complete media. Media was replaced and cells were left to grow
until colonies formed with more than 50 cells. Cells were then stained with crystal violet and
colonies with more than 50 cells were counted. The data is the average of three independent
experiments each with three replicates. Error bars are calculated based on standard error between
the three experiments.
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Figure 3.38 A549 and H460 p53 knockout cells show similar sensitivities to ATRi and DDKi
dual treatment. H460 (wild type and p53 knockout) and A549 (wild type and p53 knockout)
cells were treated for 24 hours with varying doses of VE-822 (ATRi) and XL-413 (DDKi) at a
constant ratio of 1:280 ATRi:DDKi in complete media. Media was replaced and cells were left to
grow until colonies formed with more than 50 cells. Cells were then stained with crystal violet
and colonies with more than 50 cells were counted. The x-axis is the total dose of ATRi plus
DDKi. The data is the average of three independent experiments each with three replicates. Error
bars are calculated based on standard error between the three experiments.

109

Figure 3.39 ATRi, DDKi, and dual treatment induces apoptosis in H460 cells. H460 (wild
type and p53 knockout) cells were treated for 24 hours with 125 nM VE-822 (ATRi) and 35 µM
XL-413 (DDKi) as single drugs and in combination. Protein was harvested 24 hours after
treatment and western blotting was used to examine PARP1 and tubulin.
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RAD27 is integral in maintaining genomic integrity (276,310-313), deletion of RAD27 could be
causing an increased mutational load in the rad27∆ strain that is perhaps causing some of the
observed synthetic genetic interactions. Alternatively, RAD27 may be an essential gene in yeast,
as is the mouse orthologue (301). Similar to mutation of SML1 rescuing viability of the mec1∆
strain, mutation of a separate unknown gene could rescue viability of rad27∆ strains. Perhaps
this unknown gene is causing some of the observed synthetic interactions.
Several of the synthetic genetic interactions that were uncovered in yeast have been
confirmed in recent studies. A recent genome wide SGA screen by the Boone laboratory
uncovered synthetic genetic interactions between the temperature sensitive mec1-4ts allele and
four dbf4 mutant alleles. They also uncovered interactions between the mec1 mutant and two
cdc7 mutant alleles (204). Several studies examined these interactions using human cells. A
screen found that siRNA against CDC7 sensitized U2OS cells to ATRi (314). Another screen
used siRNA against a panel of genes to look at which siRNA sensitized two cell lines to ATRi.
Interestingly, they found that knockdown of a gene involved in translesion synthesis, RAD18,
sensitized both cell lines to ATRi. However, they did not find siRNA against CDC7 or FEN1 to
sensitize the cell lines to ATRi (186).
Work detailed in Chapter 2 showed that deletion of genes involved in transcription
regulation confers a loss of fitness in terms of cell cycle progression (see Figure 3.19). In the
cse2∆ strain, the G1/S or intra-S checkpoints may be activated. A more robust effect was
observed in the srb2∆ strain, indicating a more robust G1/S or intra-S checkpoint may be
activated in the srb2∆ strain (Figure 3.19). A difference in terms of cell cycle progression was
not observed when comparing the srb2∆ and srb2∆ mec1∆ strains (See Figure 3.20). We
hypothesized that the cell cycle arrest in single mutant strains occurs because of DNA damage
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from deletion of a Mediator subunit causing a Mec1-dependent cell cycle arrest. Loss of MEC1
in the srb2∆ deletion strain probably results in loss of cell cycle arrest, which should lead to a
faster cell cycle progression. However, the slow growth of the double mutant strain may be
caused by DNA damage interfering with DNA replication. Strains lacking certain genes involved
in transcriptional regulation were observed to be hypersensitive to HU. This hypersensitivity
may be due to DNA damage/replication stress that may be activating the Mec1 checkpoint.
We further found that dbf4 or rad27 mutants were not hypersensitive to HU, suggesting
that these mutants are not defective in S phase. This was surprising, since both proteins are
integral in DNA replication. We hypothesize that there are redundant pathways that can
compensate for defective DBF4 or RAD27. There was an S phase arrest detected in dbf4 mutant
strains (Figure 3.28). These strains may be displaying a defect in DNA replication initiation,
which is slowing down progression through S phase. However, this defect is not robust enough
to cause a decrease in viability when the cells are challenged with replication stress via HU.
Knockdown of the human orthologs of genes that synthetically interact with MEC1 in
yeast sensitize a NSCLC cell line to ATRi. Therefore, the genetic interactions between MEC1
and genes encoding Mediator subunits, DBF4, and FEN1 appear be conserved between yeast and
a human NSCLC cell line. This indicates that orthologs of yeast genes that interact with MEC1
also interact with ATR in human NSCLC cells. There was an additive or slightly antagonistic
effect between DDKi and ATRi in the p53 wild type H460 and A549 cell lines. However,
synergy was observed between the two drugs in H460 p53∆ and A549 p53∆ cells. Synergy was
also observed between the drugs in the p53 null H1299 cell line. This strongly suggests a
synthetic sick phenotype between DDK and ATR, which is dependent on the absence of p53.
Perhaps the p53 checkpoint pathway was compensating for loss of the ATR checkpoint pathway.
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A combination of targeted ATRi and DDKi treatments would potentially have fewer off-target
effects and be more effective than combination of an ATR inhibitor plus a cytotoxic
chemotherapy, such as is currently being tested in clinical trials.
These genetic interaction studies show that Mec1/ATR is functionally important when
Mediator subunits or proteins involved in DNA replication/repair are defective or inhibited.
Downregulation of a Mediator subunit, DBF4, or FEN1 could have caused increased levels of
DNA damage that required ATR/MEC1 to delay the cell cycle in order for the damage to be
repaired. However, there was no evidence that Mediator subunit deletion caused DSBs or
checkpoint activation in yeast, but these techniques may not be sensitive enough to detect such
changes. Alternatively, ATR/Mec1 inhibition could be causing transcriptional defects that
require transcriptional regulators like Mediator subunits to compensate for in order to avoid a
loss in fitness. ATR/Mec1 inhibition may also be causing defects in the DDR that the DNA
repair functions of RAD27/FEN1 could be compensating for.
In the case of the DBF4 interaction, ATR/Mec1 loss/inhibition may be causing DDR
defects that could require DBF4 for compensation. These experiments did not directly probe the
mechanism behind the genetic interactions between MEC1 and DBF4. However, earlier research
has provided clues as to the reason behind the synthetic interactions. In S. cerevisiae, Mec1
phosphorylates certain residues on Mcm4 and Mcm6 that primes the helicase complex subunits
for phosphorylation by DDK (315). In our system, this could mean that Mec1 phosphorylation of
the MCM2-7 complex could be compensating for loss of MCM2-7 phosphorylation by DDK. If
Mec1 is not being expressed and DDK is defective, there may be a significant loss of
phosphorylation of the MCM helicase, which would decrease origin firing, stall replication forks,
and ultimately result in a loss in fitness. In line with this hypothesis, it has been reported that the
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dbf4-1 mutant (the allele that synthetically interacts with mec1∆) has impaired interaction with
Mcm2 and Orc2 at a semipermissive temperature. However, the mutant dbf4 can still interact
with Rad53 (76). This indicates that the DBF4 function in regulation of origin firing may be
involved in the interaction with MEC1, not the ability of DBF4 to be activated by the Mec1
checkpoint.
Another possibility is that the DDR checkpoint is impaired because of reduced
phosphorylation of CHK1. CDC7 is known to catalyze phosphorylation of Claspin in
mammalian cells, which is required for CHK1 phosphorylation (92). CHK1 is also a well-known
target of ATR phosphorylation (15), so it is also possible that DDK and ATR can compensate for
one another’s loss by phosphorylating CHK1. Inhibition of both DDK and ATR could be causing
a significant loss of CHK1 phosphorylation, which could cause a defect in the DDR and cause
the loss in fitness that was observed. In agreement with this hypothesis is a study finding that
CHK1 and ATR inhibitors are synergistic. However, this also may have to do with the regulation
of origin firing because inhibition of CDK prevented the synergy between the two inhibitors
(316). Therefore, decreases in MCM and CHK1 phosphorylation caused by inhibition of
ATR/Mec1 and DDK may be altering origin firing dynamics and causing the observed synergy
and synthetic sickness.
Several lines of evidence indicate a negative synthetic genetic interaction between ATR
and TP53. Combination of homozygous null TP53 expression and hypomorphic expression of
ATR in a mouse model potentiated the phenotype of the hypomorphic ATR mouse model (23).
Two studies showed p53-deficient cells to be more sensitive to ATR inhibitors than p53proficient cells (38,184). Also, ATR downregulation sensitized p53 deficient cells to DNA
damage to a greater extent than p53 proficient cells (317-319). Counter to this information, we
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found that p53∆ cell lines were more resistant to single agent ATRi than matched isogenic wild
type cell lines in both A549 and H460 cells (see Figure 3.36). Genes involved in
chemoresistance were more highly expressed in lung tumors with high expression of CDC7,
which indicates that CDC7 may play a role in resistance to ATR inhibition (245).
The data shows synergy between ATRi and DDKi in p53 null cells and an additive or
antagonistic effect between the two drugs in the matched isogenic cells expressing wild type p53
(see Figure 3.34). This falls in line with other research showing greater sensitization to other
drugs by ATR inhibitors in p53-deficient cells. An ATR inhibitor, AZD7762 enhanced radiosensitivity of several different cancer cell lines, and radio-sensitivity was enhanced to a greater
extent in p53 deficient cells (320). In another study, Myc-driven oncogenic stress caused ATR
and CHK1 inhibitors to be synthetic lethal. This effect was greater in p53-deficient cells (321).
Knockdown of p53 by siRNA or degradation of p53 by expression of human papillomavirus E6
protein enhanced the synergy between an ATR inhibitor, VE-821, and cisplatin (27). VE-822
also synergized more strongly with cisplatin in p53-deficient cell lines (292).
Mechanistically, p53 acts post-transcriptionally and post-translationally to reduce CDC7
expression to achieve cell cycle arrest. When CDC7 is overexpressed, which often occurs in
cancer cells, it can act in a feedback loop to reduce p53 levels (322). In our p53 wild type cell
lines, p53 may have reduced expression from the actions of DDK. In addition to the role of p53
in apoptosis pathways, it has been realized that p53 also plays a role in cell survival (323). DDK
inhibition could be increasing p53 expression, which could be acting in a pro-survival pathway
to initiate cell cycle arrest when ATR is also being inhibited.
Similarly, A549 p53∆ cells are more resistant to DDKi than matched isogenic A549 wild
type cells. In the presence of ATR, p53 may switch from a pro-survival to a pro-apoptotic
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pathway. When only DDK is inhibited, p53 is involved in an ATR-dependent pro-apoptotic
pathway. When DDK is inhibited in p53∆ cells, the p53-dependent pro-apoptotic pathway is
missing, which results in resistance to the DDKi. Intriguingly, there was not a clear difference in
resistance between H460 and H460 p53∆ matched isogenic cells. One difference between H460
and A549 cell lines is that A549 cells contain amplified MYC (300). Perhaps MYC
overexpression and p53 expression are essential for the pro-apoptotic pathway in response to
DDKi. Knockdown of ATR with RNA interference increased cell viability in response to DDKi,
indicating that ATR is necessary for cell death pathways in response to DDK inhibition (245).
This was observed in HeLa cells, which contain wild type but reduced expression of p53 from
the expression of the human papillomavirus E6 protein (324), and HCC1954 cell lines that
contain a point mutation in p53 (325). This indicates that cells expressing p53, even if p53 is
mutant or at reduced levels, can use ATR as a resistance mechanism to DDKi treatment. Perhaps
this pathway depends on expression of p53 in order to enable the pro-survival ATR pathway.
These results also indicate that wild type and p53∆ matched isogenic cells show
approximately the same pattern in sensitivity to dual ATRi and DDKi treatment (Figure 3.38).
However, the synergy observed between the two drugs in the p53∆ cell lines seemed to occur
because DDKi treatment overcame resistance to ATRi. Inhibiting DDK and ATR may prevent
late origin firing, which stalls replication forks and causes conflicts between the replication and
transcription machineries. Cells expressing p53 can deal with this stress by utilizing a p53dependent pro-survival pathway. In p53∆ cells, this stress cannot be dealt with and it ultimately
leads to p53-independent apoptosis. This is substantiated by our PARP cleavage data showing
p53-independent apoptosis in H460 cells after treatment with ATRi and DDKi (Figure 3.39). In
A549 cells, p53∆ cells are resistant to both ATRi and DDKi, but treatment with either inhibitor
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overcomes the resistance to the other. The same mechanism may also be occurring as in H460
cells, but another possibility is that ATR is involved in a pro-survival pathway when p53 is not
expressed in A549 cells. So, inhibiting ATR halts this pathway and overcomes the resistance to
DDKi.
In conclusion, the presence of synthetic genetic interactions was clearly demonstrated
between genes involved in transcriptional regulation or DNA replication and MEC1/ATR in S.
cerevisiae and human NSCLC cell lines. In yeast, there was a hypersensitization of Mediator
subunit deletion strains to HU both in a wild type and mec1∆ background. A cell cycle delay was
observed in Mediator subunit or dbf4 single mutant yeast strains. Knockdown of Mediator
subunits, DBF4, or FEN1 sensitizes human p53 null NSCLC cells to ATR inhibition. Finally,
there was an additive or antagonistic effect between ATRi and DDKi in NSCLC cells containing
wild type p53. Synergy was observed between the two drugs in matched isogenic cells
engineered to prevent expression of p53, and this seems to occur because DDKi overcame the
resistance to ATRi detected in p53∆ cells.
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CHAPTER 4 – CONCLUSIONS
In conclusion, these data highlight novel functions of Mec1 and Dbf4 in the S. cerevisiae
meiotic recombination checkpoint and functional interactions between MEC1/ATR and DBF4,
RAD27/FEN1, or Mediator subunit genes in yeast and human NSCLC cells. We found novel
functions of Mec1 and Dbf4 in preventing SIC1∆PHA–induced DNA rereplication when the
meiotic recombination checkpoint is induced by deletion of DMC1 (Chapter 2). We also found
novel functional interactions between MEC1 and genes involved in transcription regulation and
genes involved in DNA replication in S. cerevisiae. We recapitulated these results using human
orthologs of these genes in NSCLC cells. We further found that small-molecule inhibitors of
ATR and DDK were synergistic in p53 null NSCLC cells. Synergy was not observed in matched
isogenic cells expressing wild type p53 (Chapter 3). Importantly, these data demonstrate that
synthetic interactions discovered in yeast can predict synergy between two targeted therapies in
preventing growth of certain cancer cells. The simplicity of discovering novel synthetic genetic
interactions using S. cerevisiae makes the model organism a useful tool in searching for genetic
vulnerabilities in cancer cells. These studies support the many findings in the literature that ATR
and DDK are effective targets to inhibit in cancer cells.
These novel functions and functional interactions of ATR/MEC1 are significant and
contribute to a greater understanding of how ATR inhibitors function as a cancer therapy. Our
data suggests that reduced expression of FEN1, DBF4, or certain Mediator subunits heightens
sensitivity to ATRi in NSCLC cell lines. This could mean that lowered expression of these genes
in NSCLC cells could be used as a biomarker for ATRi use. The data indicating a higher
resistance to ATRi in matched isogenic p53∆ cells was unexpected. Expression of p53 could be
used as a biomarker for ATRi use if this finding is substantiated with further evidence. These
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studies also suggest that DDK inhibitors could be used to overcome the resistance to ATR
inhibitors in p53∆ cells.
Both projects leave many questions to be answered. The major question coming from the
meiosis project was the identity of the kinase responsible for catalyzing phosphorylation of Dbf4
and presumably Sld3 to prevent DNA rereplication when the meiotic recombination checkpoint
is activated. Other kinases could be examined in our system by mutating kinases likely to be
responsible for these phosphorylation events in the SIC1∆PHA dmc1∆ background. If mutation of
the kinase results in DNA rereplication when sporulation is induced, then the kinase could be
looked at further. It would be useful to examine Dbf4 and Sld3 phosphorylation using a strain
with a mutant kinase and comparing it with a WT strain after induction of meiosis. Future studies
could also delve into whether it is the function of Dbf4, Sld3, or both proteins in preventing
DNA rereplication. We only studied a strain containing phosphorylation site mutants of both
genes at once. We hypothesize that both would be involved and that mutation of DBF4 alone or
SLD3 alone would both cause a return to the rereplication phenotype in SIC1∆PHA dmc1∆ cells.
More research could also be performed to discover if these proteins are involved in prevention of
DNA rereplication during meiosis in human cells.
There is still much work to be done for the synthetic interaction project. It will be
important to examine the mechanism by which ATR and DDK inhibition prevents colony
formation. PARP cleavage data suggests that ATRi and DDKi dual treatment induces apoptosis
in H460 cells, but this may not be the major mechanism, especially in other cell lines. It will be
essential to verify apoptosis using other techniques, such as flow cytometry. Cell cycle analysis
would be useful, which could indicate if the inhibitors induce cell cycle arrest. A translational
study could include treatment of a p53 null NSCLC xenograft mouse model with ATRi and
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DDKi as single treatments and comparing with dual treatment. Future studies could also include
testing structurally different ATR and DDK inhibitors to ensure that the mechanism of synergy is
not due to off-target effects. It will be beneficial to more thoroughly study the functional
interactions of ATR and Mediator subunits or FEN1 in cancer cells. We hypothesize that small
molecule inhibitors of FEN1 or Mediator subunits will synergize with ATR inhibitors. When
FEN1 inhibitors are more thoroughly tested and when Mediator subunit inhibitors become
available, they could be tested for synergy with ATRi. These approaches could provide strategies
to enhance the effectiveness of ATRi-based cancer therapy.
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Mec1 is a protein kinase in S. cerevisiae that is critical for the DNA damage checkpoint
response, and is the yeast orthologue of the human ATR protein. Cancer cells rely on ATR to
arrest the cell cycle and allow sufficient time to repair DNA damage before proceeding through
the cell cycle, and ATR inhibitors have been developed as possible anti-cancer agents. DBF4 is
the regulatory subunit of DBF4-dependent kinase (DDK) that regulates initiation of DNA
replication and is overexpressed in a number of different cancer types. To better understand ATR
and DBF4 function, we took advantage of yeast genetics to examine the role of Mec1 and Dbf4
in prevention of DNA rereplication during meiosis. We found that Dbf4 phosphorylation sites
and Mec1 were essential for prevention of DNA rereplication when the meiotic recombination
checkpoint was activated by deletion of DMC1. We further found evidence that Dbf4 was
phosphorylated by a kinase other than the canonical Rad53 or Mek1 protein kinases.
We also examined genes that synthetically interact with MEC1 in order to better
understand the function of Mec1 during the normal cell cycle. Synthetic genetic interactions
occur when fitness is not affected by a single mutation of one of two genes, but when both of the
two genes are mutated a significant loss in fitness occurs. Among the many genes identified to

164
synthetically interact with MEC1, many are involved in mRNA transcription, including several
subunits of the Mediator complex. We also found genes involved in DNA replication to
synthetically interact with MEC1, such as RAD27 and DBF4. We assessed whether these
synthetic interactions exist in human non-small cell lung cancer (NSCLC) cell lines. We
discovered that inhibitors of ATR and DDK act synergistically in p53 null cell lines but not in
p53 wild type cell lines. This data suggests a synthetic interaction between ATR and genes
involved in transcriptional regulation or DNA replication in NSCLC cells that is dependent on
the absence of p53. These studies have provided insight into novel targets to inhibit in
combination with ATR inhibitors as a treatment regimen for NSCLC.
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